

WEBVTT

NOTE duration:"00:56:13"

NOTE recognizability:0.815

NOTE language:en-us

NOTE Confidence: 0.9023378835

00:00:03.200 --> 00:00:05.590 All right. Good afternoon, everybody,

NOTE Confidence: 0.9023378835

00:00:05.590 --> 00:00:07.980 and welcome to the classical

NOTE Confidence: 0.9023378835

00:00:08.056 --> 00:00:10.446 hematology review of the American

NOTE Confidence: 0.9023378835

00:00:10.446 --> 00:00:13.296 Society of Hematology meeting in 2022.

NOTE Confidence: 0.9023378835

00:00:13.296 --> 00:00:15.576 Thank you for joining us.

NOTE Confidence: 0.9023378835

00:00:15.580 --> 00:00:16.860 My name is Robert Bona.

NOTE Confidence: 0.9023378835

00:00:16.860 --> 00:00:19.668 I work here at Yale in the section of

NOTE Confidence: 0.9023378835

00:00:19.668 --> 00:00:22.119 hematology and I'm very excited and happy

NOTE Confidence: 0.9023378835

00:00:22.119 --> 00:00:24.540 to introduce our three speakers today.

NOTE Confidence: 0.9023378835

00:00:24.540 --> 00:00:26.521 I will be brief with their introductions

NOTE Confidence: 0.9023378835

00:00:26.521 --> 00:00:28.531 since I don't want to take away

NOTE Confidence: 0.9023378835

00:00:28.531 --> 00:00:30.193 time from the important things that

NOTE Confidence: 0.9023378835

00:00:30.253 --> 00:00:32.136 they're going to talk with us about.

NOTE Confidence: 0.9023378835

00:00:32.140 --> 00:00:34.366 Lila van Doren. We'll begin our discussion.
NOTE Confidence: 0.9023378835

00:00:34.370 --> 00:00:35.030 Lila joined.
NOTE Confidence: 0.9023378835

00:00:35.030 --> 00:00:37.010 All three of our faculty actually
NOTE Confidence: 0.9023378835

00:00:37.010 --> 00:00:38.869 have joined the classical hematology
NOTE Confidence: 0.9023378835

00:00:38.869 --> 00:00:41.143 program at Yale this academic year.
NOTE Confidence: 0.9023378835

00:00:41.150 --> 00:00:43.187 And Lila joined us from Columbia and
NOTE Confidence: 0.9023378835

00:00:43.187 --> 00:00:45.251 she brings a wealth of experience
NOTE Confidence: 0.9023378835

00:00:45.251 --> 00:00:46.747 and knowledge with her.
NOTE Confidence: 0.9023378835

00:00:46.750 --> 00:00:49.262 And at Yale she is going to be
NOTE Confidence: 0.9023378835

00:00:49.262 --> 00:00:51.791 focusing on sickle cell diseases and
NOTE Confidence: 0.9023378835

00:00:51.791 --> 00:00:54.071 iron disorders of iron hemostasis
NOTE Confidence: 0.9023378835

00:00:54.071 --> 00:00:56.370 in particular iron homeostasis in
NOTE Confidence: 0.9023378835

00:00:56.370 --> 00:01:00.442 particular in the area of of Women's Health.
NOTE Confidence: 0.9023378835

00:01:00.442 --> 00:01:01.864 Doctor Gashua,
NOTE Confidence: 0.9023378835

00:01:01.864 --> 00:01:03.286 Yale fellow.
NOTE Confidence: 0.9023378835

00:01:03.290 --> 00:01:05.240 And graduate of the Harvard Public

NOTE Confidence: 0.9023378835

00:01:05.240 --> 00:01:07.664 School of Health is focusing his work

NOTE Confidence: 0.9023378835

00:01:07.664 --> 00:01:10.530 research work here at Yale on decision

NOTE Confidence: 0.9023378835

00:01:10.530 --> 00:01:13.660 science analysis and hematologic disorders.

NOTE Confidence: 0.9023378835

00:01:13.660 --> 00:01:15.704 And Annie Sharda joined us from the

NOTE Confidence: 0.9023378835

00:01:15.704 --> 00:01:17.400 Beth Israel Deaconess Medical Center.

NOTE Confidence: 0.9023378835

00:01:17.400 --> 00:01:20.376 He has a active laboratory program

NOTE Confidence: 0.9023378835

00:01:20.376 --> 00:01:22.923 looking at endothelial function and

NOTE Confidence: 0.9023378835

00:01:22.923 --> 00:01:25.328 in particular the expression and

NOTE Confidence: 0.9023378835

00:01:25.328 --> 00:01:27.860 secretion of von Willebrand factor.

NOTE Confidence: 0.9023378835

00:01:27.860 --> 00:01:28.444 So again,

NOTE Confidence: 0.9023378835

00:01:28.444 --> 00:01:28.736 we're,

NOTE Confidence: 0.9023378835

00:01:28.736 --> 00:01:31.153 I'm very excited to to to have them

NOTE Confidence: 0.9023378835

00:01:31.153 --> 00:01:33.633 present their work to us today or their.

NOTE Confidence: 0.9023378835

00:01:33.640 --> 00:01:37.245 Their review of some of the ash.

NOTE Confidence: 0.9023378835

00:01:37.250 --> 00:01:40.256 Up hot abstracts and please put

NOTE Confidence: 0.9023378835

00:01:40.256 --> 00:01:43.093 your questions in the chat room
NOTE Confidence: 0.9023378835

00:01:43.093 --> 00:01:45.550 or in the Q&A and we'll get to
NOTE Confidence: 0.9023378835

00:01:45.550 --> 00:01:47.020 those at the end of the session.
NOTE Confidence: 0.9023378835

00:01:47.020 --> 00:01:49.324 Each of our presenters will present
NOTE Confidence: 0.9023378835

00:01:49.324 --> 00:01:51.631 for about 15 minutes and then
NOTE Confidence: 0.9023378835

00:01:51.631 --> 00:01:53.737 we'll take questions at the end.
NOTE Confidence: 0.9023378835

00:01:53.740 --> 00:01:55.452 So without further ado,
NOTE Confidence: 0.9023378835

00:01:55.452 --> 00:01:56.736 Doctor Van Dorn,
NOTE Confidence: 0.9023378835

00:01:56.740 --> 00:01:58.364 would you like to get us started?
NOTE Confidence: 0.81773288666667

00:01:59.840 --> 00:02:05.906 Share my screen. And. There we go.
NOTE Confidence: 0.81773288666667

00:02:05.906 --> 00:02:09.178 OK, these are my disclosures. All right.
NOTE Confidence: 0.81773288666667

00:02:09.180 --> 00:02:10.530 These are the two abstracts that
NOTE Confidence: 0.81773288666667

00:02:10.530 --> 00:02:12.280 I'm going to be discussing today,
NOTE Confidence: 0.81773288666667

00:02:12.280 --> 00:02:13.936 so we'll just jump into it.
NOTE Confidence: 0.81773288666667

00:02:13.940 --> 00:02:16.412 The first abstract is focused on
NOTE Confidence: 0.81773288666667

00:02:16.412 --> 00:02:18.060 inherited thrombophilia and pregnancy,

NOTE Confidence: 0.817732886666667
00:02:18.060 --> 00:02:21.640 anticoagulation and thrombophilia testing.
NOTE Confidence: 0.817732886666667
00:02:21.640 --> 00:02:24.080 So I wanted to start out with the case first.
NOTE Confidence: 0.817732886666667
00:02:24.080 --> 00:02:26.952 It's a 38 year old patient who presents
NOTE Confidence: 0.817732886666667
00:02:26.952 --> 00:02:29.138 for evaluation at 8 weeks gestation.
NOTE Confidence: 0.817732886666667
00:02:29.140 --> 00:02:31.384 She's the history of three miscarriages
NOTE Confidence: 0.817732886666667
00:02:31.384 --> 00:02:33.787 in the first trimester anti phospholipid
NOTE Confidence: 0.817732886666667
00:02:33.787 --> 00:02:36.319 antibody testing was previously negative but
NOTE Confidence: 0.817732886666667
00:02:36.319 --> 00:02:39.279 she was found to be positive for Factor 5,
NOTE Confidence: 0.817732886666667
00:02:39.280 --> 00:02:40.558 Leiden heterozygous mutation.
NOTE Confidence: 0.817732886666667
00:02:40.558 --> 00:02:43.540 And the question is would you recommend
NOTE Confidence: 0.817732886666667
00:02:43.605 --> 00:02:45.825 anticoagulation during pregnancy for this
NOTE Confidence: 0.817732886666667
00:02:45.825 --> 00:02:48.979 patient to increase her chance of live birth?
NOTE Confidence: 0.817732886666667
00:02:48.980 --> 00:02:51.122 So the background is that studies
NOTE Confidence: 0.817732886666667
00:02:51.122 --> 00:02:52.550 have shown an association.
NOTE Confidence: 0.817732886666667
00:02:52.550 --> 00:02:54.920 Between recurrent miscarriage and inherited
NOTE Confidence: 0.817732886666667

00:02:54.920 --> 00:02:57.620 thrombophilia for women with a PLS,
NOTE Confidence: 0.817732886666667

00:02:57.620 --> 00:02:59.879 we know that the use of heparin or low
NOTE Confidence: 0.817732886666667

00:02:59.879 --> 00:03:01.332 molecular weight heparin and combined
NOTE Confidence: 0.817732886666667

00:03:01.332 --> 00:03:03.594 with low dose aspirin is an effective
NOTE Confidence: 0.817732886666667

00:03:03.594 --> 00:03:05.518 treatment for recurrent miscarriage.
NOTE Confidence: 0.817732886666667

00:03:05.520 --> 00:03:08.411 And the thought about the role of
NOTE Confidence: 0.817732886666667

00:03:08.411 --> 00:03:09.650 thrombophilia recurrent miscarriage
NOTE Confidence: 0.817732886666667

00:03:09.712 --> 00:03:11.889 is that it can be explained partially
NOTE Confidence: 0.817732886666667

00:03:11.889 --> 00:03:14.502 by the concept of thrombosis of the
NOTE Confidence: 0.817732886666667

00:03:14.502 --> 00:03:16.118 microvasculature of the placenta.
NOTE Confidence: 0.817732886666667

00:03:16.120 --> 00:03:18.486 And so it is thought that anticoagulant
NOTE Confidence: 0.817732886666667

00:03:18.486 --> 00:03:20.504 therapy might reduce miscarriages and
NOTE Confidence: 0.817732886666667

00:03:20.504 --> 00:03:22.869 adverse pregnancy outcomes in patients
NOTE Confidence: 0.817732886666667

00:03:22.869 --> 00:03:24.799 with inherited thrombophilia as well.
NOTE Confidence: 0.817732886666667

00:03:24.800 --> 00:03:25.208 However,
NOTE Confidence: 0.817732886666667

00:03:25.208 --> 00:03:27.248 there's a lack of solid

NOTE Confidence: 0.817732886666667
00:03:27.248 --> 00:03:28.880 evidence for this practice.
NOTE Confidence: 0.817732886666667
00:03:28.880 --> 00:03:32.536 And so in 2010 a study was published,
NOTE Confidence: 0.817732886666667
00:03:32.540 --> 00:03:35.676 a life study that was a randomized
NOTE Confidence: 0.817732886666667
00:03:35.680 --> 00:03:37.393 placebo-controlled study investigating
NOTE Confidence: 0.817732886666667
00:03:37.393 --> 00:03:40.248 whether aspirin plus low molecular
NOTE Confidence: 0.817732886666667
00:03:40.248 --> 00:03:42.672 weight heparin or aspirin alone
NOTE Confidence: 0.817732886666667
00:03:42.672 --> 00:03:44.400 combined oh compared to placebo
NOTE Confidence: 0.817732886666667
00:03:44.400 --> 00:03:46.050 would improve the live birth.
NOTE Confidence: 0.817732886666667
00:03:46.050 --> 00:03:47.019 Among 364 women,
NOTE Confidence: 0.817732886666667
00:03:47.019 --> 00:03:48.957 so there were three different arms
NOTE Confidence: 0.817732886666667
00:03:48.957 --> 00:03:50.962 and what this study showed was
NOTE Confidence: 0.817732886666667
00:03:50.962 --> 00:03:52.958 that there was no difference in
NOTE Confidence: 0.817732886666667
00:03:52.958 --> 00:03:54.842 the live birth rates between the
NOTE Confidence: 0.817732886666667
00:03:54.842 --> 00:03:56.926 study groups with the relative risk
NOTE Confidence: 0.817732886666667
00:03:56.926 --> 00:04:00.070 of 1.03 and in patient specific.
NOTE Confidence: 0.817732886666667

00:04:00.070 --> 00:04:00.438 Thrombophilia,
NOTE Confidence: 0.817732886666667

00:04:00.438 --> 00:04:02.278 there was also no difference,
NOTE Confidence: 0.817732886666667

00:04:02.280 --> 00:04:04.155 although the number of patients
NOTE Confidence: 0.817732886666667

00:04:04.155 --> 00:04:06.552 in the study with an inherited
NOTE Confidence: 0.817732886666667

00:04:06.552 --> 00:04:09.646 thrombophilia were was very low and so.
NOTE Confidence: 0.817732886666667

00:04:09.650 --> 00:04:12.305 Which brings us to the a life two study,
NOTE Confidence: 0.817732886666667

00:04:12.310 --> 00:04:13.678 the first abstract,
NOTE Confidence: 0.817732886666667

00:04:13.678 --> 00:04:16.110 which was a late breaking abstract
NOTE Confidence: 0.817732886666667

00:04:16.110 --> 00:04:17.905 at ASH in December 2022,
NOTE Confidence: 0.817732886666667

00:04:17.905 --> 00:04:20.105 and it was ten years in the making.
NOTE Confidence: 0.817732886666667

00:04:20.110 --> 00:04:22.758 So the objective of the A life two
NOTE Confidence: 0.817732886666667

00:04:22.758 --> 00:04:25.064 study was specifically to evaluate
NOTE Confidence: 0.817732886666667

00:04:25.064 --> 00:04:27.026 the efficacy of low molecular weight
NOTE Confidence: 0.817732886666667

00:04:27.026 --> 00:04:29.508 heparin and women with an inherited
NOTE Confidence: 0.817732886666667

00:04:29.508 --> 00:04:31.280 thrombophilia with recurrent miscarriage.
NOTE Confidence: 0.817732886666667

00:04:31.280 --> 00:04:33.268 And so the way this study was

NOTE Confidence: 0.817732886666667

00:04:33.268 --> 00:04:35.516 designed is that patients who had a

NOTE Confidence: 0.817732886666667

00:04:35.516 --> 00:04:37.514 history of two or more miscarriages

NOTE Confidence: 0.817732886666667

00:04:37.583 --> 00:04:39.559 with an inherited thrombophilia,

NOTE Confidence: 0.817732886666667

00:04:39.560 --> 00:04:41.576 no more than seven weeks gestational

NOTE Confidence: 0.817732886666667

00:04:41.576 --> 00:04:42.920 age could be enrolled.

NOTE Confidence: 0.817732886666667

00:04:42.920 --> 00:04:44.838 They were randomized 1 to one to

NOTE Confidence: 0.817732886666667

00:04:44.838 --> 00:04:46.752 receive either a low molecular weight

NOTE Confidence: 0.817732886666667

00:04:46.752 --> 00:04:48.804 heparin and those are the different

NOTE Confidence: 0.817732886666667

00:04:48.804 --> 00:04:51.164 ones that that were used in the study

NOTE Confidence: 0.817732886666667

00:04:51.164 --> 00:04:53.147 plus the standard of pregnancy care

NOTE Confidence: 0.817732886666667

00:04:53.147 --> 00:04:55.800 or a standard of pregnancy care alone.

NOTE Confidence: 0.817732886666667

00:04:55.800 --> 00:04:57.966 The outcomes was the primary efficacy

NOTE Confidence: 0.817732886666667

00:04:57.966 --> 00:05:00.159 outcome was the live birth rate,

NOTE Confidence: 0.817732886666667

00:05:00.160 --> 00:05:00.988 secondary efficacy.

NOTE Confidence: 0.817732886666667

00:05:00.988 --> 00:05:02.644 This miscarriage or adverse

NOTE Confidence: 0.817732886666667

00:05:02.644 --> 00:05:04.625 obstetric outcomes and then safety
NOTE Confidence: 0.817732886666667

00:05:04.625 --> 00:05:05.960 was looked at as well.
NOTE Confidence: 0.817732886666667

00:05:05.960 --> 00:05:07.490 And so these are the
NOTE Confidence: 0.817732886666667

00:05:07.490 --> 00:05:08.714 characteristics of the patients.
NOTE Confidence: 0.817732886666667

00:05:08.720 --> 00:05:11.000 The mean age was 33 and
NOTE Confidence: 0.817732886666667

00:05:11.000 --> 00:05:12.520 the majority of patients
NOTE Confidence: 0.885496186875

00:05:12.607 --> 00:05:15.775 actually had three or more miscarriages.
NOTE Confidence: 0.885496186875

00:05:15.780 --> 00:05:17.575 The most common inherited thrombophilia
NOTE Confidence: 0.885496186875

00:05:17.575 --> 00:05:19.915 was the factor 5 Leiden heterozygous
NOTE Confidence: 0.885496186875

00:05:19.915 --> 00:05:22.335 followed by prothrombin gene mutation,
NOTE Confidence: 0.885496186875

00:05:22.340 --> 00:05:24.420 heterozygous protein ESTA efficiency
NOTE Confidence: 0.885496186875

00:05:24.420 --> 00:05:28.216 and then a mix of antithrombin combined
NOTE Confidence: 0.885496186875

00:05:28.216 --> 00:05:31.804 thrombophilias and then protein C deficiency.
NOTE Confidence: 0.885496186875

00:05:31.810 --> 00:05:34.258 And the outcome of the study was that there
NOTE Confidence: 0.885496186875

00:05:34.258 --> 00:05:36.675 was no difference between the standard of
NOTE Confidence: 0.885496186875

00:05:36.675 --> 00:05:39.068 care and low molecular weight heparin plus

NOTE Confidence: 0.885496186875

00:05:39.068 --> 00:05:41.576 standard of care in the live birth rate.

NOTE Confidence: 0.885496186875

00:05:41.576 --> 00:05:43.934 So the odds ratio was 1.04 when

NOTE Confidence: 0.885496186875

00:05:43.934 --> 00:05:45.869 this was adjusted for age.

NOTE Confidence: 0.885496186875

00:05:45.870 --> 00:05:47.616 So less than or greater than

NOTE Confidence: 0.885496186875

00:05:47.616 --> 00:05:49.530 or equal to 36 years old,

NOTE Confidence: 0.885496186875

00:05:49.530 --> 00:05:51.945 the number of miscarriages or the center.

NOTE Confidence: 0.885496186875

00:05:51.950 --> 00:05:54.134 So if the patient was treated at a

NOTE Confidence: 0.885496186875

00:05:54.134 --> 00:05:56.107 tertiary center or a non tertiary center,

NOTE Confidence: 0.885496186875

00:05:56.110 --> 00:05:59.064 or by country UK versus the Netherlands,

NOTE Confidence: 0.885496186875

00:05:59.070 --> 00:06:00.555 there was still no difference

NOTE Confidence: 0.885496186875

00:06:00.555 --> 00:06:02.040 between the live birth rate.

NOTE Confidence: 0.885496186875

00:06:02.040 --> 00:06:04.768 In the different arms.

NOTE Confidence: 0.885496186875

00:06:04.770 --> 00:06:06.595 In terms of the differences

NOTE Confidence: 0.885496186875

00:06:06.595 --> 00:06:07.690 in adverse effects,

NOTE Confidence: 0.885496186875

00:06:07.690 --> 00:06:10.266 there were more adverse effects in patients

NOTE Confidence: 0.885496186875

00:06:10.266 --> 00:06:12.250 receiving low molecular weight heparin,

NOTE Confidence: 0.885496186875

00:06:12.250 --> 00:06:13.782 such as easy bruising,

NOTE Confidence: 0.885496186875

00:06:13.782 --> 00:06:14.548 skin reactions,

NOTE Confidence: 0.885496186875

00:06:14.550 --> 00:06:17.886 that injection site and minor bleeding.

NOTE Confidence: 0.885496186875

00:06:17.890 --> 00:06:19.997 And so the conclusions of this study

NOTE Confidence: 0.885496186875

00:06:19.997 --> 00:06:22.005 was that low molecular weight heparin

NOTE Confidence: 0.885496186875

00:06:22.005 --> 00:06:24.709 did not result in a higher life birth

NOTE Confidence: 0.885496186875

00:06:24.709 --> 00:06:26.732 rate in women who had greater than

NOTE Confidence: 0.885496186875

00:06:26.732 --> 00:06:29.665 or equal to two pregnancy losses and

NOTE Confidence: 0.885496186875

00:06:29.665 --> 00:06:31.039 confirmed inherited thrombophilia.

NOTE Confidence: 0.885496186875

00:06:31.040 --> 00:06:33.280 And the recommendation is to not use

NOTE Confidence: 0.885496186875

00:06:33.280 --> 00:06:35.487 low molecular weight heparin in women

NOTE Confidence: 0.885496186875

00:06:35.487 --> 00:06:37.457 with recurrent pregnancy loss and

NOTE Confidence: 0.885496186875

00:06:37.457 --> 00:06:38.763 confirmed inherited thrombophilias

NOTE Confidence: 0.885496186875

00:06:38.763 --> 00:06:40.607 to prevent pregnancy loss.

NOTE Confidence: 0.885496186875

00:06:40.610 --> 00:06:44.348 And so this also speaks to,

NOTE Confidence: 0.885496186875
00:06:44.350 --> 00:06:45.408 not against,
NOTE Confidence: 0.885496186875
00:06:45.408 --> 00:06:48.053 the routine testing for inherited
NOTE Confidence: 0.885496186875
00:06:48.053 --> 00:06:50.302 thrombophilia in women with
NOTE Confidence: 0.885496186875
00:06:50.302 --> 00:06:52.030 recurrent pregnancy loss.
NOTE Confidence: 0.885496186875
00:06:52.030 --> 00:06:54.226 So that is the first abstract.
NOTE Confidence: 0.885496186875
00:06:54.230 --> 00:06:56.360 The second abstract will focus on
NOTE Confidence: 0.885496186875
00:06:56.360 --> 00:06:58.114 sickle cell disease, diarrhea,
NOTE Confidence: 0.885496186875
00:06:58.114 --> 00:07:00.850 and diminished ovarian reserve.
NOTE Confidence: 0.885496186875
00:07:00.850 --> 00:07:02.029 So second case,
NOTE Confidence: 0.885496186875
00:07:02.029 --> 00:07:05.200 a patient comes to you 12 years old.
NOTE Confidence: 0.885496186875
00:07:05.200 --> 00:07:07.671 She has a history of avascular necrosis
NOTE Confidence: 0.885496186875
00:07:07.671 --> 00:07:10.101 and very rare vasal clusive crises
NOTE Confidence: 0.885496186875
00:07:10.101 --> 00:07:12.266 she presents for initial visit.
NOTE Confidence: 0.885496186875
00:07:12.270 --> 00:07:14.225 During the visit you discussed
NOTE Confidence: 0.885496186875
00:07:14.225 --> 00:07:16.180 the importance of hydroxyurea as
NOTE Confidence: 0.885496186875

00:07:16.242 --> 00:07:17.978 a disease modifying therapy.
NOTE Confidence: 0.885496186875

00:07:17.980 --> 00:07:19.768 She notes that her previous provider
NOTE Confidence: 0.885496186875

00:07:19.768 --> 00:07:22.175 told her she does not require hydroxyurea
NOTE Confidence: 0.885496186875

00:07:22.175 --> 00:07:24.105 therapy due to infrequent basal,
NOTE Confidence: 0.885496186875

00:07:24.110 --> 00:07:24.916 occlusive crises.
NOTE Confidence: 0.885496186875

00:07:24.916 --> 00:07:25.722 But furthermore,
NOTE Confidence: 0.885496186875

00:07:25.722 --> 00:07:28.820 most concern for her is a Facebook,
NOTE Confidence: 0.885496186875

00:07:28.820 --> 00:07:30.955 Facebook group that she's a part of
NOTE Confidence: 0.885496186875

00:07:30.955 --> 00:07:32.680 recommends not taking it for those
NOTE Confidence: 0.885496186875

00:07:32.680 --> 00:07:34.437 who desire to have children in the
NOTE Confidence: 0.885496186875

00:07:34.499 --> 00:07:36.317 future as it leads to infertility.
NOTE Confidence: 0.885496186875

00:07:36.320 --> 00:07:39.731 So there is quite a bit of evidence for
NOTE Confidence: 0.885496186875

00:07:39.731 --> 00:07:41.897 hydroxyurea and fertility in males.
NOTE Confidence: 0.885496186875

00:07:41.900 --> 00:07:45.356 We know that it leads to lower sperm counts.
NOTE Confidence: 0.885496186875

00:07:45.360 --> 00:07:47.898 Which improves with cessation of hydroxyurea.
NOTE Confidence: 0.885496186875

00:07:47.900 --> 00:07:50.020 But we don't have a lot of data

NOTE Confidence: 0.885496186875

00:07:50.020 --> 00:07:52.005 available for the use of hydroxyurea

NOTE Confidence: 0.885496186875

00:07:52.005 --> 00:07:54.093 and diminished ovarian reserve in in

NOTE Confidence: 0.885496186875

00:07:54.152 --> 00:07:56.570 female patients with sickle cell disease.

NOTE Confidence: 0.885496186875

00:07:56.570 --> 00:07:59.180 And so from the evidence that we do have,

NOTE Confidence: 0.885496186875

00:07:59.180 --> 00:08:01.343 we do know that patients with sickle

NOTE Confidence: 0.885496186875

00:08:01.343 --> 00:08:03.723 cell disease have a higher rate of

NOTE Confidence: 0.885496186875

00:08:03.723 --> 00:08:05.119 diminished ovarian reserve compared

NOTE Confidence: 0.885496186875

00:08:05.119 --> 00:08:07.020 to those who are age and age,

NOTE Confidence: 0.885496186875

00:08:07.020 --> 00:08:10.149 race and sex match to to patients

NOTE Confidence: 0.885496186875

00:08:10.149 --> 00:08:12.300 with sickle cell disease,

NOTE Confidence: 0.885496186875

00:08:12.300 --> 00:08:14.372 there is much more of a sharper

NOTE Confidence: 0.885496186875

00:08:14.372 --> 00:08:15.260 trajectory of decline.

NOTE Confidence: 0.885496186875

00:08:15.260 --> 00:08:16.744 Of diminished ovarian reserve.

NOTE Confidence: 0.885496186875

00:08:16.744 --> 00:08:19.526 And the thought is that this is and

NOTE Confidence: 0.885496186875

00:08:19.526 --> 00:08:21.486 it was a theory again it had not

NOTE Confidence: 0.786146952608696

00:08:21.553 --> 00:08:22.999 previously been proven.
NOTE Confidence: 0.786146952608696

00:08:23.000 --> 00:08:25.544 The thought is that this is related to
NOTE Confidence: 0.786146952608696

00:08:25.544 --> 00:08:27.660 hemolysis and anemia based occlusion.
NOTE Confidence: 0.786146952608696

00:08:27.660 --> 00:08:30.000 Basically any organ that can be
NOTE Confidence: 0.786146952608696

00:08:30.000 --> 00:08:32.200 affected by sickle cell disease,
NOTE Confidence: 0.786146952608696

00:08:32.200 --> 00:08:33.460 which is every organ in the body,
NOTE Confidence: 0.786146952608696

00:08:33.460 --> 00:08:35.204 the ovaries included, can.
NOTE Confidence: 0.786146952608696

00:08:35.204 --> 00:08:37.384 This can all lead to
NOTE Confidence: 0.786146952608696

00:08:37.384 --> 00:08:39.099 diminished ovarian reserve.
NOTE Confidence: 0.786146952608696

00:08:39.100 --> 00:08:41.116 And one thing that we don't know
NOTE Confidence: 0.786146952608696

00:08:41.116 --> 00:08:43.400 is that is hydroxy hydroxyurea,
NOTE Confidence: 0.786146952608696

00:08:43.400 --> 00:08:45.276 is it a friend or a foe?
NOTE Confidence: 0.786146952608696

00:08:45.280 --> 00:08:48.220 So we know that hydroxyurea causes.
NOTE Confidence: 0.786146952608696

00:08:48.220 --> 00:08:49.800 Reduction and disease severity.
NOTE Confidence: 0.786146952608696

00:08:49.800 --> 00:08:53.299 So in theory it should be preventing this
NOTE Confidence: 0.786146952608696

00:08:53.299 --> 00:08:55.924 accelerated age-related loss of eggs,

NOTE Confidence: 0.786146952608696
00:08:55.930 --> 00:08:59.129 but does it actually also contribute to
NOTE Confidence: 0.786146952608696
00:08:59.129 --> 00:09:01.578 the accelerated age-related loss of eggs?
NOTE Confidence: 0.786146952608696
00:09:01.578 --> 00:09:03.870 And that is the question that
NOTE Confidence: 0.786146952608696
00:09:03.943 --> 00:09:05.887 we don't know the answer to.
NOTE Confidence: 0.786146952608696
00:09:05.890 --> 00:09:08.260 And so this study was actually
NOTE Confidence: 0.786146952608696
00:09:08.260 --> 00:09:10.390 this is a background study.
NOTE Confidence: 0.786146952608696
00:09:10.390 --> 00:09:13.407 So this was done from the MULTICENTRIC
NOTE Confidence: 0.786146952608696
00:09:13.407 --> 00:09:15.935 study of hydroxyurea and it was
NOTE Confidence: 0.786146952608696
00:09:15.935 --> 00:09:18.257 the pivotal trial that showed the
NOTE Confidence: 0.786146952608696
00:09:18.257 --> 00:09:20.532 benefits of hydroxyurea in patients
NOTE Confidence: 0.786146952608696
00:09:20.532 --> 00:09:23.250 to present to prevent organ damage.
NOTE Confidence: 0.786146952608696
00:09:23.250 --> 00:09:25.490 And what this shows here is that
NOTE Confidence: 0.786146952608696
00:09:25.490 --> 00:09:27.889 you can see at every age level
NOTE Confidence: 0.786146952608696
00:09:27.889 --> 00:09:29.589 starting from 20 to 25,
NOTE Confidence: 0.786146952608696
00:09:29.590 --> 00:09:32.550 we see that there's an age associated decline
NOTE Confidence: 0.786146952608696

00:09:32.550 --> 00:09:35.634 in the AM H level which is a marker of.
NOTE Confidence: 0.786146952608696

00:09:35.640 --> 00:09:37.896 Administration ovarian reserve when the MH
NOTE Confidence: 0.786146952608696

00:09:37.896 --> 00:09:40.716 level is less than 1.1 nanograms per ML.
NOTE Confidence: 0.786146952608696

00:09:40.716 --> 00:09:42.361 This contributes to the definition
NOTE Confidence: 0.786146952608696

00:09:42.361 --> 00:09:44.258 of diminished ovarian reserve.
NOTE Confidence: 0.786146952608696

00:09:44.260 --> 00:09:46.444 The dark lines here are the median
NOTE Confidence: 0.786146952608696

00:09:46.444 --> 00:09:48.312 age control match ADH levels and
NOTE Confidence: 0.786146952608696

00:09:48.312 --> 00:09:50.328 the the the Gray boxes here these
NOTE Confidence: 0.786146952608696

00:09:50.395 --> 00:09:52.200 are patients with sickle cell.
NOTE Confidence: 0.786146952608696

00:09:52.200 --> 00:09:55.780 So we see even at age 20 to 25 years old,
NOTE Confidence: 0.786146952608696

00:09:55.780 --> 00:09:58.727 there is lower a MH levels compared
NOTE Confidence: 0.786146952608696

00:09:58.727 --> 00:10:01.394 to the controls and it's not until
NOTE Confidence: 0.786146952608696

00:10:01.394 --> 00:10:04.119 age 40 to 46 where we see that
NOTE Confidence: 0.786146952608696

00:10:04.120 --> 00:10:06.238 the controls as well as patients.
NOTE Confidence: 0.786146952608696

00:10:06.240 --> 00:10:08.550 Sickle cell disease both have
NOTE Confidence: 0.786146952608696

00:10:08.550 --> 00:10:13.030 AMH levels of less than 1.1.

NOTE Confidence: 0.786146952608696

00:10:13.030 --> 00:10:15.186 And so we what do we know?

NOTE Confidence: 0.786146952608696

00:10:15.190 --> 00:10:17.549 We know that patients with sickle cell

NOTE Confidence: 0.786146952608696

00:10:17.549 --> 00:10:19.639 have higher rates of diminished ovarian

NOTE Confidence: 0.786146952608696

00:10:19.639 --> 00:10:22.669 reserve at least starting 25 to 30 years old.

NOTE Confidence: 0.786146952608696

00:10:22.670 --> 00:10:24.118 The relationship between diminished

NOTE Confidence: 0.786146952608696

00:10:24.118 --> 00:10:25.566 ovarian reserve and pregnancy

NOTE Confidence: 0.786146952608696

00:10:25.566 --> 00:10:27.475 outcomes and live births in sickle

NOTE Confidence: 0.786146952608696

00:10:27.475 --> 00:10:28.890 cell does require further study

NOTE Confidence: 0.786146952608696

00:10:28.890 --> 00:10:30.266 because that doesn't answer the

NOTE Confidence: 0.786146952608696

00:10:30.266 --> 00:10:32.195 question we don't have an answer to.

NOTE Confidence: 0.786146952608696

00:10:32.195 --> 00:10:34.385 But the data regarding venata toxicity

NOTE Confidence: 0.786146952608696

00:10:34.385 --> 00:10:37.227 in women with sickle cell disease who

NOTE Confidence: 0.786146952608696

00:10:37.227 --> 00:10:39.327 are taking hydroxyurea is limited,

NOTE Confidence: 0.786146952608696

00:10:39.330 --> 00:10:41.225 and it's thought that hydroxyurea

NOTE Confidence: 0.786146952608696

00:10:41.225 --> 00:10:43.120 use might be a surrogate.

NOTE Confidence: 0.786146952608696

00:10:43.120 --> 00:10:45.325 The disease severity rather than
NOTE Confidence: 0.786146952608696

00:10:45.325 --> 00:10:47.089 the hydroxyurea itself causing
NOTE Confidence: 0.786146952608696

00:10:47.089 --> 00:10:48.549 diminished ovarian reserve.
NOTE Confidence: 0.786146952608696

00:10:48.550 --> 00:10:52.134 And so this is an next abstract and
NOTE Confidence: 0.786146952608696

00:10:52.134 --> 00:10:55.492 their study aimed to assess this
NOTE Confidence: 0.786146952608696

00:10:55.492 --> 00:10:58.447 does hydroxyurea and does basal
NOTE Confidence: 0.786146952608696

00:10:58.447 --> 00:11:01.062 occlusive crises cause diminished
NOTE Confidence: 0.786146952608696

00:11:01.062 --> 00:11:03.090 ovarian follicle density?
NOTE Confidence: 0.786146952608696

00:11:03.090 --> 00:11:05.556 And in girls and young females
NOTE Confidence: 0.786146952608696

00:11:05.556 --> 00:11:07.200 with sickle cell disease?
NOTE Confidence: 0.786146952608696

00:11:07.200 --> 00:11:08.608 And so this study,
NOTE Confidence: 0.786146952608696

00:11:08.608 --> 00:11:10.720 it was designed 88 patients with
NOTE Confidence: 0.786146952608696

00:11:10.794 --> 00:11:13.349 hemoglobin s s genotype underwent
NOTE Confidence: 0.786146952608696

00:11:13.349 --> 00:11:14.882 ovarian tissue cryopreservation
NOTE Confidence: 0.786146952608696

00:11:14.882 --> 00:11:17.430 prior to stem cell transplant.
NOTE Confidence: 0.786146952608696

00:11:17.430 --> 00:11:19.466 Ovarian tissue was evaluated

NOTE Confidence: 0.786146952608696

00:11:19.466 --> 00:11:21.502 histologically by two independent

NOTE Confidence: 0.786146952608696

00:11:21.502 --> 00:11:23.465 investigators and the primary

NOTE Confidence: 0.786146952608696

00:11:23.465 --> 00:11:25.650 outcome was ovarian follicle density

NOTE Confidence: 0.786146952608696

00:11:25.650 --> 00:11:28.200 and here are the characteristics.

NOTE Confidence: 0.786146952608696

00:11:28.200 --> 00:11:29.760 So most of the patients had

NOTE Confidence: 0.786146952608696

00:11:29.760 --> 00:11:30.540 not reached puberty.

NOTE Confidence: 0.786146952608696

00:11:30.540 --> 00:11:33.991 Puberty of 45% were treated with hydroxyurea

NOTE Confidence: 0.786146952608696

00:11:33.991 --> 00:11:37.427 with a median dose of 23 milligrams.

NOTE Confidence: 0.786146952608696

00:11:37.430 --> 00:11:39.295 It's per kilogram and the

NOTE Confidence: 0.786146952608696

00:11:39.295 --> 00:11:41.160 vast majority of patients did

NOTE Confidence: 0.692494187142857

00:11:41.230 --> 00:11:43.130 report vasal clusive crisis.

NOTE Confidence: 0.692494187142857

00:11:43.130 --> 00:11:45.986 Of those patients who had vasoactive crisis,

NOTE Confidence: 0.692494187142857

00:11:45.990 --> 00:11:48.454 49% were on hydroxyurea.

NOTE Confidence: 0.692494187142857

00:11:48.454 --> 00:11:50.940 94% of patients receive pack red

NOTE Confidence: 0.692494187142857

00:11:50.940 --> 00:11:53.209 blood cell transfusion at some point

NOTE Confidence: 0.692494187142857

00:11:53.209 --> 00:11:55.540 with the median applied units of 22.
NOTE Confidence: 0.692494187142857

00:11:55.540 --> 00:11:57.668 And so the outcome of the study showed
NOTE Confidence: 0.692494187142857

00:11:57.668 --> 00:11:59.731 that the follicle density was similar
NOTE Confidence: 0.692494187142857

00:11:59.731 --> 00:12:01.939 in the hydroxyurea group compared to
NOTE Confidence: 0.692494187142857

00:12:01.997 --> 00:12:03.977 those without hydroxyurea exposure.
NOTE Confidence: 0.692494187142857

00:12:03.980 --> 00:12:05.640 But for the first time,
NOTE Confidence: 0.692494187142857

00:12:05.640 --> 00:12:08.184 a study did show that the follicle density
NOTE Confidence: 0.692494187142857

00:12:08.184 --> 00:12:09.809 was significantly higher in patients
NOTE Confidence: 0.692494187142857

00:12:09.809 --> 00:12:11.993 who did not have vasal occlusive crisis.
NOTE Confidence: 0.692494187142857

00:12:12.000 --> 00:12:14.532 And so this suggests that it's
NOTE Confidence: 0.692494187142857

00:12:14.532 --> 00:12:16.809 actually the disease itself rather
NOTE Confidence: 0.692494187142857

00:12:16.809 --> 00:12:19.359 than hydroxyurea that is leading
NOTE Confidence: 0.692494187142857

00:12:19.359 --> 00:12:21.399 to diminished ovarian reserve.
NOTE Confidence: 0.692494187142857

00:12:21.400 --> 00:12:23.248 And so the conclusions of this
NOTE Confidence: 0.692494187142857

00:12:23.248 --> 00:12:24.900 study as as I said,
NOTE Confidence: 0.692494187142857

00:12:24.900 --> 00:12:27.294 were the hydroxyurea exposure did not

NOTE Confidence: 0.692494187142857
00:12:27.294 --> 00:12:29.799 appear to reduce cortical follicle density
NOTE Confidence: 0.692494187142857
00:12:29.799 --> 00:12:32.319 in females with sickle cell disease.
NOTE Confidence: 0.692494187142857
00:12:32.320 --> 00:12:33.420 And for the first time,
NOTE Confidence: 0.692494187142857
00:12:33.420 --> 00:12:35.226 the study could show an influence
NOTE Confidence: 0.692494187142857
00:12:35.226 --> 00:12:37.499 of VOC on ovarian follicle density,
NOTE Confidence: 0.692494187142857
00:12:37.500 --> 00:12:39.803 possibly related to reduced blood flow and
NOTE Confidence: 0.692494187142857
00:12:39.803 --> 00:12:42.157 all the effects of sickle cell disease.
NOTE Confidence: 0.692494187142857
00:12:42.160 --> 00:12:45.946 What we don't know is what.
NOTE Confidence: 0.692494187142857
00:12:45.950 --> 00:12:46.822 What the?
NOTE Confidence: 0.692494187142857
00:12:46.822 --> 00:12:49.002 Ovarian follicle density would look
NOTE Confidence: 0.692494187142857
00:12:49.002 --> 00:12:52.492 like in a patient who has been on
NOTE Confidence: 0.692494187142857
00:12:52.492 --> 00:12:55.390 hydroxyurea for a much longer duration,
NOTE Confidence: 0.692494187142857
00:12:55.390 --> 00:12:57.987 because the median age of the patients
NOTE Confidence: 0.692494187142857
00:12:57.987 --> 00:13:00.530 in this study was nine years old.
NOTE Confidence: 0.692494187142857
00:13:00.530 --> 00:13:03.008 And the evidence that we have for
NOTE Confidence: 0.692494187142857

00:13:03.008 --> 00:13:04.481 diminished ovarian reserve and
NOTE Confidence: 0.692494187142857

00:13:04.481 --> 00:13:06.196 patients with sickle cell really
NOTE Confidence: 0.692494187142857

00:13:06.196 --> 00:13:08.219 starts at age between 20 and 25,
NOTE Confidence: 0.692494187142857

00:13:08.220 --> 00:13:09.990 that multicenter study of hydroxyurea
NOTE Confidence: 0.692494187142857

00:13:09.990 --> 00:13:11.760 that I showed you previously.
NOTE Confidence: 0.863884502777778

00:13:13.860 --> 00:13:15.920 And lastly, longitudinal data are
NOTE Confidence: 0.863884502777778

00:13:15.920 --> 00:13:18.546 needed to evaluate if genotype and
NOTE Confidence: 0.863884502777778

00:13:18.546 --> 00:13:20.542 severity of disease accelerate
NOTE Confidence: 0.863884502777778

00:13:20.542 --> 00:13:22.039 diminished ovarian reserve.
NOTE Confidence: 0.863884502777778

00:13:22.040 --> 00:13:23.510 Thank you and that's it.
NOTE Confidence: 0.8675334875

00:13:30.250 --> 00:13:32.770 It is a pleasure to follow Doctor Vandoren,
NOTE Confidence: 0.8675334875

00:13:32.770 --> 00:13:35.857 and so I will take over the screen sharing.
NOTE Confidence: 0.91067636

00:13:39.360 --> 00:13:41.960 Beautiful. Good afternoon, everyone.
NOTE Confidence: 0.91067636

00:13:41.960 --> 00:13:43.080 Thank you for joining.
NOTE Confidence: 0.91067636

00:13:43.080 --> 00:13:44.460 My name is George Joshua.
NOTE Confidence: 0.91067636

00:13:44.460 --> 00:13:46.542 I am an assistant professor of

NOTE Confidence: 0.91067636

00:13:46.542 --> 00:13:48.459 medicine and hematology here at Yale,

NOTE Confidence: 0.91067636

00:13:48.460 --> 00:13:52.107 and I'm the Pi for a quantitative

NOTE Confidence: 0.91067636

00:13:52.107 --> 00:13:54.699 decision sign and some lab.

NOTE Confidence: 0.91067636

00:13:54.700 --> 00:13:56.100 So without further ado,

NOTE Confidence: 0.91067636

00:13:56.100 --> 00:13:58.900 let's talk about 3 hard hitting abstracts.

NOTE Confidence: 0.91067636

00:13:58.900 --> 00:14:00.540 I have no disclosures.

NOTE Confidence: 0.91067636

00:14:00.540 --> 00:14:03.170 The first, we're gonna go and talk

NOTE Confidence: 0.91067636

00:14:03.170 --> 00:14:04.980 through cold gluten and disease

NOTE Confidence: 0.91067636

00:14:05.047 --> 00:14:06.889 and immune thrombocytopenia.

NOTE Confidence: 0.91067636

00:14:06.890 --> 00:14:09.450 We're going to start with all of these,

NOTE Confidence: 0.91067636

00:14:09.450 --> 00:14:10.790 by the way, our orals,

NOTE Confidence: 0.91067636

00:14:10.790 --> 00:14:11.870 one of them is a plenary,

NOTE Confidence: 0.91067636

00:14:11.870 --> 00:14:14.206 as I'll point out in the next talk.

NOTE Confidence: 0.91067636

00:14:14.210 --> 00:14:16.858 And the last talk will be focused on

NOTE Confidence: 0.91067636

00:14:16.858 --> 00:14:19.183 a phenomenal study actually done by

NOTE Confidence: 0.91067636

00:14:19.183 --> 00:14:21.571 a trainee from the Cleveland Clinic.
NOTE Confidence: 0.91067636

00:14:21.580 --> 00:14:23.505 So talking about patient reported
NOTE Confidence: 0.91067636

00:14:23.505 --> 00:14:26.282 outcomes 1st and septima abuse and our
NOTE Confidence: 0.91067636

00:14:26.282 --> 00:14:28.257 patients with cold agglutinin disease.
NOTE Confidence: 0.91067636

00:14:28.260 --> 00:14:31.277 And so this is the schematic for
NOTE Confidence: 0.91067636

00:14:31.277 --> 00:14:35.014 cadenza and this is a trial that
NOTE Confidence: 0.91067636

00:14:35.014 --> 00:14:37.370 focused on transfusion independent
NOTE Confidence: 0.91067636

00:14:37.370 --> 00:14:40.748 individuals with cold agglutinin disease.
NOTE Confidence: 0.91067636

00:14:40.750 --> 00:14:42.414 You can see part A and Part B.
NOTE Confidence: 0.91067636

00:14:42.420 --> 00:14:44.772 Part A has been reported on
NOTE Confidence: 0.91067636

00:14:44.772 --> 00:14:46.720 previously at this year's Ash,
NOTE Confidence: 0.91067636

00:14:46.720 --> 00:14:47.840 Alexander Roth and colleagues
NOTE Confidence: 0.91067636

00:14:47.840 --> 00:14:48.960 reported on Part B,
NOTE Confidence: 0.91067636

00:14:48.960 --> 00:14:51.813 and so that that is what I'll focus on.
NOTE Confidence: 0.91067636

00:14:51.820 --> 00:14:54.716 But for anchoring,
NOTE Confidence: 0.91067636

00:14:54.716 --> 00:14:58.412 part A was a double-blind period of

NOTE Confidence: 0.91067636

00:14:58.412 --> 00:15:01.179 randomization to sitemap versus placebo.

NOTE Confidence: 0.91067636

00:15:01.180 --> 00:15:02.890 You see that there's a screening

NOTE Confidence: 0.91067636

00:15:02.890 --> 00:15:04.351 observation period there of six

NOTE Confidence: 0.91067636

00:15:04.351 --> 00:15:05.696 weeks leading into that study.

NOTE Confidence: 0.91067636

00:15:05.700 --> 00:15:08.394 And Part B was then the continuation

NOTE Confidence: 0.91067636

00:15:08.394 --> 00:15:10.716 of the open label phase component

NOTE Confidence: 0.91067636

00:15:10.716 --> 00:15:13.120 of patients who are on similar map

NOTE Confidence: 0.91067636

00:15:13.120 --> 00:15:15.373 on similar mab and patients who are

NOTE Confidence: 0.91067636

00:15:15.373 --> 00:15:17.245 on placebo going to similar map.

NOTE Confidence: 0.91067636

00:15:17.250 --> 00:15:18.948 So in the open label extension,

NOTE Confidence: 0.91067636

00:15:18.950 --> 00:15:19.482 Part B,

NOTE Confidence: 0.91067636

00:15:19.482 --> 00:15:21.078 all of those patients who completed

NOTE Confidence: 0.91067636

00:15:21.078 --> 00:15:23.178 part A were eligible then to receive

NOTE Confidence: 0.91067636

00:15:23.178 --> 00:15:24.983 biweekly doses and this was weight

NOTE Confidence: 0.91067636

00:15:24.983 --> 00:15:27.089 based as you can see in front of you.

NOTE Confidence: 0.91067636

00:15:27.090 --> 00:15:28.546 What we'll focus on in the next slide
NOTE Confidence: 0.91067636

00:15:28.546 --> 00:15:30.087 will be the patient reported outcome
NOTE Confidence: 0.91067636

00:15:30.090 --> 00:15:34.216 endpoints and there are five of them.
NOTE Confidence: 0.91067636

00:15:34.220 --> 00:15:36.092 And so the objective here again is to
NOTE Confidence: 0.91067636

00:15:36.092 --> 00:15:38.329 look at transfusion independent patients.
NOTE Confidence: 0.91067636

00:15:38.330 --> 00:15:40.689 This is cadenza trial as opposed to
NOTE Confidence: 0.91067636

00:15:40.689 --> 00:15:42.114 transfusion dependent called gluten
NOTE Confidence: 0.91067636

00:15:42.114 --> 00:15:44.238 disease patients that would be cardinal.
NOTE Confidence: 0.91067636

00:15:44.240 --> 00:15:46.102 And the follow up here is immediate
NOTE Confidence: 0.91067636

00:15:46.102 --> 00:15:47.784 treatment over 99 weeks and the
NOTE Confidence: 0.91067636

00:15:47.784 --> 00:15:49.164 patient reported outcomes are you
NOTE Confidence: 0.91067636

00:15:49.164 --> 00:15:51.080 can see them in front of you here,
NOTE Confidence: 0.91067636

00:15:51.080 --> 00:15:53.430 the facet fatigue, the PGS,
NOTE Confidence: 0.91067636

00:15:53.430 --> 00:15:53.838 the PG,
NOTE Confidence: 0.91067636

00:15:53.838 --> 00:15:55.834 I see the 12 item SF12 and I noted
NOTE Confidence: 0.91067636

00:15:55.834 --> 00:15:57.364 for specific reasons that you'll

NOTE Confidence: 0.91067636

00:15:57.364 --> 00:15:59.769 see on the next slide what that

NOTE Confidence: 0.91067636

00:15:59.769 --> 00:16:01.639 includes both physical and mental

NOTE Confidence: 0.91067636

00:16:01.639 --> 00:16:03.164 component scores and finally

NOTE Confidence: 0.91067636

00:16:03.164 --> 00:16:05.099 the euroqol visual analog scale.

NOTE Confidence: 0.804984824285714

00:16:07.330 --> 00:16:11.130 And here are the baselines and the patient

NOTE Confidence: 0.804984824285714

00:16:11.130 --> 00:16:13.990 sample sizes and the mean effects.

NOTE Confidence: 0.804984824285714

00:16:13.990 --> 00:16:15.862 And in the right column here I put for

NOTE Confidence: 0.804984824285714

00:16:15.862 --> 00:16:17.574 you what the investigators reported

NOTE Confidence: 0.804984824285714

00:16:17.574 --> 00:16:19.384 as clinically important changes that

NOTE Confidence: 0.804984824285714

00:16:19.384 --> 00:16:21.436 were derived in private prior studies.

NOTE Confidence: 0.804984824285714

00:16:21.440 --> 00:16:24.002 So we can actually interpret what

NOTE Confidence: 0.804984824285714

00:16:24.002 --> 00:16:26.139 is clearly clinically meaningful or

NOTE Confidence: 0.804984824285714

00:16:26.139 --> 00:16:27.426 potentially clinically meaningful.

NOTE Confidence: 0.804984824285714

00:16:27.426 --> 00:16:30.494 So the mean age of these patients

NOTE Confidence: 0.804984824285714

00:16:30.494 --> 00:16:32.608 was 67.80% of them were women and

NOTE Confidence: 0.804984824285714

00:16:32.608 --> 00:16:34.965 you can see the facet fatigue score
NOTE Confidence: 0.804984824285714

00:16:34.965 --> 00:16:36.701 with an improvement of 8.8.
NOTE Confidence: 0.804984824285714

00:16:36.701 --> 00:16:37.656 Right in the middle there,
NOTE Confidence: 0.804984824285714

00:16:37.660 --> 00:16:39.406 with the standard error of 2.1,
NOTE Confidence: 0.804984824285714

00:16:39.406 --> 00:16:41.486 you'll note a reported clinically
NOTE Confidence: 0.804984824285714

00:16:41.486 --> 00:16:43.150 important change which is
NOTE Confidence: 0.804984824285714

00:16:43.215 --> 00:16:45.357 available here is more than five.
NOTE Confidence: 0.804984824285714

00:16:45.360 --> 00:16:47.656 You have to think about that in the
NOTE Confidence: 0.804984824285714

00:16:47.656 --> 00:16:50.120 context of the standard error now,
NOTE Confidence: 0.804984824285714

00:16:50.120 --> 00:16:51.137 the SF 12,
NOTE Confidence: 0.804984824285714

00:16:51.137 --> 00:16:52.832 the physical and the mental
NOTE Confidence: 0.804984824285714

00:16:52.832 --> 00:16:54.070 cognitive scores as well.
NOTE Confidence: 0.804984824285714

00:16:54.070 --> 00:16:56.722 Hit above the report of clinically
NOTE Confidence: 0.804984824285714

00:16:56.722 --> 00:16:58.863 important changes with statement lab
NOTE Confidence: 0.804984824285714

00:16:58.863 --> 00:17:01.578 use and you'll see an added about 4.9
NOTE Confidence: 0.804984824285714

00:17:01.578 --> 00:17:04.468 points for the physical component,

NOTE Confidence: 0.804984824285714
00:17:04.470 --> 00:17:06.798 4.0 points for the mental component.
NOTE Confidence: 0.804984824285714
00:17:06.800 --> 00:17:09.576 And the last piece within the rows you
NOTE Confidence: 0.804984824285714
00:17:09.576 --> 00:17:12.498 see the EQ visual analog score scale
NOTE Confidence: 0.804984824285714
00:17:12.498 --> 00:17:15.180 again and add an improvement there,
NOTE Confidence: 0.804984824285714
00:17:15.180 --> 00:17:17.476 but there is not a study that has
NOTE Confidence: 0.804984824285714
00:17:17.476 --> 00:17:18.907 derived invalidated a reported
NOTE Confidence: 0.804984824285714
00:17:18.907 --> 00:17:20.499 clinically important change here.
NOTE Confidence: 0.804984824285714
00:17:20.500 --> 00:17:22.420 And so that is that's why I put
NOTE Confidence: 0.804984824285714
00:17:22.420 --> 00:17:24.020 that as a non applicable.
NOTE Confidence: 0.804984824285714
00:17:24.020 --> 00:17:26.843 Now if you look at PGI S&P GIC,
NOTE Confidence: 0.804984824285714
00:17:26.843 --> 00:17:30.140 you can see too that for the pgis
NOTE Confidence: 0.804984824285714
00:17:30.140 --> 00:17:32.076 31% there was a 31% improvement
NOTE Confidence: 0.804984824285714
00:17:32.076 --> 00:17:34.556 in the proportion of patients
NOTE Confidence: 0.804984824285714
00:17:34.560 --> 00:17:36.124 reporting nor mild fatigue.
NOTE Confidence: 0.804984824285714
00:17:36.124 --> 00:17:39.349 So it more patients by the conclusion of
NOTE Confidence: 0.804984824285714

00:17:39.349 --> 00:17:42.142 the study reported no or mild fatigue
NOTE Confidence: 0.804984824285714

00:17:42.142 --> 00:17:44.571 and the delta there was from about
NOTE Confidence: 0.804984824285714

00:17:44.571 --> 00:17:47.689 mid 40s to mid 70s percentage wise.
NOTE Confidence: 0.804984824285714

00:17:47.689 --> 00:17:50.605 And finally the PGIC by the end of
NOTE Confidence: 0.804984824285714

00:17:50.605 --> 00:17:52.866 the study 71 of the patients who were
NOTE Confidence: 0.804984824285714

00:17:52.866 --> 00:17:55.062 reporting a positive change from the
NOTE Confidence: 0.804984824285714

00:17:55.062 --> 00:17:57.405 baseline from where they had started from.
NOTE Confidence: 0.804984824285714

00:17:57.410 --> 00:17:58.550 So take home.
NOTE Confidence: 0.804984824285714

00:17:58.550 --> 00:18:01.537 So the condenser part BPRO data it
NOTE Confidence: 0.804984824285714

00:18:01.537 --> 00:18:03.982 appears that September map demonstrate
NOTE Confidence: 0.804984824285714

00:18:03.982 --> 00:18:06.578 can demonstrate benefits that are
NOTE Confidence: 0.804984824285714

00:18:06.578 --> 00:18:08.940 associated with its use specifically on
NOTE Confidence: 0.804984824285714

00:18:08.940 --> 00:18:11.170 fatigue and overall quality of life.
NOTE Confidence: 0.804984824285714

00:18:11.170 --> 00:18:12.952 The benefits appear to maintain for
NOTE Confidence: 0.804984824285714

00:18:12.952 --> 00:18:14.793 more than one year and mentioned
NOTE Confidence: 0.804984824285714

00:18:14.793 --> 00:18:16.569 median follow up in 99 weeks.

NOTE Confidence: 0.804984824285714

00:18:16.570 --> 00:18:19.372 And and this is important patients

NOTE Confidence: 0.804984824285714

00:18:19.372 --> 00:18:21.240 previously previously treated with

NOTE Confidence: 0.804984824285714

00:18:21.312 --> 00:18:23.584 placebo did demonstrate a brisk

NOTE Confidence: 0.804984824285714

00:18:23.584 --> 00:18:25.726 PR O improvement in Part B.

NOTE Confidence: 0.804984824285714

00:18:25.730 --> 00:18:27.106 So these are the patients who went from.

NOTE Confidence: 0.804984824285714

00:18:27.110 --> 00:18:28.818 Cebu to sitemap so they are able

NOTE Confidence: 0.804984824285714

00:18:28.818 --> 00:18:30.774 to catch up to the patients who

NOTE Confidence: 0.804984824285714

00:18:30.774 --> 00:18:32.224 had been on sitemap before.

NOTE Confidence: 0.66837746

00:18:34.890 --> 00:18:36.526 Moving to a plenary,

NOTE Confidence: 0.66837746

00:18:36.526 --> 00:18:40.550 this is Edgar Tigard and ITP Egard Tiger mod.

NOTE Confidence: 0.66837746

00:18:40.550 --> 00:18:43.838 Is an IG1 FC fragment and a natural

NOTE Confidence: 0.66837746

00:18:43.838 --> 00:18:46.990 ligand for the neonatal FC receptor.

NOTE Confidence: 0.66837746

00:18:46.990 --> 00:18:48.502 It's engineered to competitively

NOTE Confidence: 0.66837746

00:18:48.502 --> 00:18:51.701 bind to FCRN with a high affinity and

NOTE Confidence: 0.66837746

00:18:51.701 --> 00:18:54.287 prevent the recycling of endogenous IG,

NOTE Confidence: 0.66837746

00:18:54.290 --> 00:18:56.150 but it doesn't affect albumin.
NOTE Confidence: 0.66837746

00:18:56.150 --> 00:18:57.944 This drug has been improved in
NOTE Confidence: 0.66837746

00:18:57.944 --> 00:18:59.727 myasthenia gravis and here I present
NOTE Confidence: 0.66837746

00:18:59.727 --> 00:19:01.568 to you the results from advanced 4
NOTE Confidence: 0.66837746

00:19:01.568 --> 00:19:03.409 which is a phase three multicenter,
NOTE Confidence: 0.66837746

00:19:03.410 --> 00:19:06.428 double-blind, placebo-controlled RCT.
NOTE Confidence: 0.66837746

00:19:06.430 --> 00:19:09.000 In patients with immune thrombocytopenia,
NOTE Confidence: 0.66837746

00:19:09.000 --> 00:19:11.214 generally speaking when we think about
NOTE Confidence: 0.66837746

00:19:11.214 --> 00:19:12.690 pathogenic autoantibodies and ITP,
NOTE Confidence: 0.66837746

00:19:12.690 --> 00:19:14.070 we think about increased platelet
NOTE Confidence: 0.66837746

00:19:14.070 --> 00:19:15.914 clearance as one of the mechanisms
NOTE Confidence: 0.66837746

00:19:15.914 --> 00:19:17.570 in inhibiting platelet production
NOTE Confidence: 0.66837746

00:19:17.570 --> 00:19:19.226 and impacting platelet function.
NOTE Confidence: 0.66837746

00:19:19.230 --> 00:19:21.310 You see all of those listed in a
NOTE Confidence: 0.66837746

00:19:21.310 --> 00:19:23.448 schematic to the left and then on
NOTE Confidence: 0.66837746

00:19:23.448 --> 00:19:26.010 the right the the schematic for the

NOTE Confidence: 0.66837746

00:19:26.089 --> 00:19:29.835 recycling of your endogenous IG and

NOTE Confidence: 0.66837746

00:19:29.835 --> 00:19:34.618 where F guys taking mod is is acting.

NOTE Confidence: 0.66837746

00:19:34.620 --> 00:19:35.992 Now for this RCT,

NOTE Confidence: 0.66837746

00:19:35.992 --> 00:19:38.640 you had to have been an adult,

NOTE Confidence: 0.66837746

00:19:38.640 --> 00:19:40.930 so at least 18 years of age and to have

NOTE Confidence: 0.66837746

00:19:40.997 --> 00:19:43.589 chronic or persistent ITP and as a reminder,

NOTE Confidence: 0.66837746

00:19:43.590 --> 00:19:44.196 chronic ITP,

NOTE Confidence: 0.66837746

00:19:44.196 --> 00:19:46.620 ITP of duration at 12 months or more,

NOTE Confidence: 0.66837746

00:19:46.620 --> 00:19:50.084 persistent is 3 to 3 to 12 months.

NOTE Confidence: 0.66837746

00:19:50.090 --> 00:19:52.071 You have to have two platelet counts

NOTE Confidence: 0.66837746

00:19:52.071 --> 00:19:54.162 of less than 30,000 during the

NOTE Confidence: 0.66837746

00:19:54.162 --> 00:19:55.664 screening period and the screening

NOTE Confidence: 0.66837746

00:19:55.664 --> 00:19:57.330 period lasted 2 weeks for this trial.

NOTE Confidence: 0.66837746

00:19:57.330 --> 00:20:00.120 And you had to have been on at least

NOTE Confidence: 0.66837746

00:20:00.120 --> 00:20:02.185 two ITP treatments or one prior

NOTE Confidence: 0.66837746

00:20:02.185 --> 00:20:03.940 treatment and one concurrent treatment.
NOTE Confidence: 0.66837746

00:20:03.940 --> 00:20:05.950 Those are the eligibility criteria,
NOTE Confidence: 0.66837746

00:20:05.950 --> 00:20:07.708 an important point for this trial
NOTE Confidence: 0.66837746

00:20:07.708 --> 00:20:09.934 that's not listed on the slide because
NOTE Confidence: 0.66837746

00:20:09.934 --> 00:20:11.594 it was an eligibility criteria.
NOTE Confidence: 0.66837746

00:20:11.600 --> 00:20:12.950 But once the trial started,
NOTE Confidence: 0.66837746

00:20:12.950 --> 00:20:15.242 these patients needed to be maintained
NOTE Confidence: 0.66837746

00:20:15.242 --> 00:20:17.937 on the same dosing of whatever they
NOTE Confidence: 0.66837746

00:20:17.937 --> 00:20:20.127 were on previously for their IT.
NOTE Confidence: 0.66837746

00:20:20.130 --> 00:20:21.638 Be without those escalations.
NOTE Confidence: 0.66837746

00:20:21.638 --> 00:20:24.297 So the treatment period was 24 weeks
NOTE Confidence: 0.66837746

00:20:24.297 --> 00:20:26.259 and patients were randomized 2 to
NOTE Confidence: 0.66837746

00:20:26.259 --> 00:20:29.255 one to Edgar Sigma 10 milligrams per
NOTE Confidence: 0.66837746

00:20:29.255 --> 00:20:31.203 kilogram intravenously versus placebo.
NOTE Confidence: 0.66837746

00:20:31.210 --> 00:20:33.802 And there was a period as you can see
NOTE Confidence: 0.66837746

00:20:33.802 --> 00:20:36.986 in front of you here where you could

NOTE Confidence: 0.66837746

00:20:36.986 --> 00:20:39.859 have those adjustments of I've got taken mod.

NOTE Confidence: 0.66837746

00:20:39.860 --> 00:20:40.838 At the end of the trial,

NOTE Confidence: 0.66837746

00:20:40.840 --> 00:20:41.996 as we'll talk about,

NOTE Confidence: 0.66837746

00:20:41.996 --> 00:20:43.730 there's a follow-up period and more

NOTE Confidence: 0.66837746

00:20:43.786 --> 00:20:46.534 than 90% went on to enroll in the

NOTE Confidence: 0.66837746

00:20:46.534 --> 00:20:48.653 Open label extension called Advanced

NOTE Confidence: 0.66837746

00:20:48.653 --> 00:20:52.115 Plus that is in its early phases now.

NOTE Confidence: 0.66837746

00:20:52.120 --> 00:20:53.605 These are the baseline characteristics

NOTE Confidence: 0.66837746

00:20:53.605 --> 00:20:54.496 for these patients.

NOTE Confidence: 0.66837746

00:20:54.500 --> 00:20:56.978 You can see that they match

NOTE Confidence: 0.66837746

00:20:56.978 --> 00:20:58.217 up reasonably well.

NOTE Confidence: 0.66837746

00:20:58.220 --> 00:20:59.072 In particular,

NOTE Confidence: 0.66837746

00:20:59.072 --> 00:21:02.054 I'll point out The Who bleeding scores

NOTE Confidence: 0.66837746

00:21:02.054 --> 00:21:04.614 pretty similar across the board patients

NOTE Confidence: 0.66837746

00:21:04.614 --> 00:21:07.739 with three or more prior ITP therapies,

NOTE Confidence: 0.66837746

00:21:07.740 --> 00:21:09.380 patients that we technically think
NOTE Confidence: 0.66837746

00:21:09.380 --> 00:21:11.520 of as quote UN quote refractory.
NOTE Confidence: 0.66837746

00:21:11.520 --> 00:21:13.984 That's how the trial referred to them
NOTE Confidence: 0.66837746

00:21:13.984 --> 00:21:16.889 as well and that's about 6 to 7 out
NOTE Confidence: 0.66837746

00:21:16.889 --> 00:21:19.737 of 10 patients in both arms and to
NOTE Confidence: 0.66837746

00:21:19.737 --> 00:21:21.732 the concurrent ITP therapy types.
NOTE Confidence: 0.66837746

00:21:21.740 --> 00:21:23.908 Baseline being utilized, steroids,
NOTE Confidence: 0.66837746

00:21:23.908 --> 00:21:24.450 tipra,
NOTE Confidence: 0.66837746

00:21:24.450 --> 00:21:24.838 is,
NOTE Confidence: 0.66837746

00:21:24.838 --> 00:21:26.390 and other immune suppressants
NOTE Confidence: 0.66837746

00:21:26.390 --> 00:21:27.702 all reasonably nicely matched,
NOTE Confidence: 0.66837746

00:21:27.702 --> 00:21:29.670 and so here in this case,
NOTE Confidence: 0.66837746

00:21:29.670 --> 00:21:32.764 you can see that this random allocation
NOTE Confidence: 0.66837746

00:21:32.764 --> 00:21:35.247 has probably served its purpose
NOTE Confidence: 0.66837746

00:21:35.247 --> 00:21:37.395 of controlling for confounding.
NOTE Confidence: 0.66837746

00:21:37.400 --> 00:21:39.045 The endpoints here are the

NOTE Confidence: 0.66837746

00:21:39.045 --> 00:21:40.690 here's the primary endpoint and

NOTE Confidence: 0.8144564045

00:21:40.748 --> 00:21:42.393 also key secondary endpoints all

NOTE Confidence: 0.8144564045

00:21:42.393 --> 00:21:44.900 to say that all platelets specific

NOTE Confidence: 0.8144564045

00:21:44.900 --> 00:21:46.484 secondary endpoints were met.

NOTE Confidence: 0.8144564045

00:21:46.484 --> 00:21:48.860 The primary endpoint was the proportion

NOTE Confidence: 0.8144564045

00:21:48.924 --> 00:21:50.922 of patients with a sustained count

NOTE Confidence: 0.8144564045

00:21:50.922 --> 00:21:53.350 response and as typical in ITP literature,

NOTE Confidence: 0.8144564045

00:21:53.350 --> 00:21:55.674 this was defined as a platelet count

NOTE Confidence: 0.8144564045

00:21:55.674 --> 00:21:58.447 of 50,000 or more and in this case on

NOTE Confidence: 0.8144564045

00:21:58.447 --> 00:22:01.180 at least four out of 6 clinic visits

NOTE Confidence: 0.8144564045

00:22:01.180 --> 00:22:03.460 during the conclusion of this period,

NOTE Confidence: 0.8144564045

00:22:03.460 --> 00:22:05.658 in this case weeks 19 through 24,

NOTE Confidence: 0.8144564045

00:22:05.660 --> 00:22:07.200 of course in the absence of ITP.

NOTE Confidence: 0.8144564045

00:22:07.200 --> 00:22:09.186 Others and then key secondary endpoints

NOTE Confidence: 0.8144564045

00:22:09.186 --> 00:22:11.350 include cumulative weeks of Disease Control,

NOTE Confidence: 0.8144564045

00:22:11.350 --> 00:22:12.946 so just the number of weeks
NOTE Confidence: 0.8144564045

00:22:12.946 --> 00:22:13.744 of Disease Control,
NOTE Confidence: 0.8144564045

00:22:13.750 --> 00:22:15.460 something called sustained
NOTE Confidence: 0.8144564045

00:22:15.460 --> 00:22:17.170 platelet count response.
NOTE Confidence: 0.8144564045

00:22:17.170 --> 00:22:19.336 And the durable sustained platelet count
NOTE Confidence: 0.8144564045

00:22:19.336 --> 00:22:21.493 response which is just extending that
NOTE Confidence: 0.8144564045

00:22:21.493 --> 00:22:23.768 risk exposure period out to week 17.
NOTE Confidence: 0.8144564045

00:22:23.770 --> 00:22:25.814 And so there's a significance on the
NOTE Confidence: 0.8144564045

00:22:25.814 --> 00:22:27.722 platelet count and all of these the
NOTE Confidence: 0.8144564045

00:22:27.722 --> 00:22:29.714 take homes from this plenary abstract
NOTE Confidence: 0.8144564045

00:22:29.714 --> 00:22:31.727 whereas that lowering total IG levels
NOTE Confidence: 0.8144564045

00:22:31.727 --> 00:22:33.653 by targeting the neonatal FC receptor
NOTE Confidence: 0.8144564045

00:22:33.653 --> 00:22:35.407 appears to demonstrate statistically
NOTE Confidence: 0.8144564045

00:22:35.407 --> 00:22:37.239 significant improvements in primary
NOTE Confidence: 0.8144564045

00:22:37.239 --> 00:22:38.985 and secondary platelet endpoints.
NOTE Confidence: 0.8144564045

00:22:38.985 --> 00:22:41.905 The drug also appears to be well tolerated

NOTE Confidence: 0.8144564045

00:22:41.905 --> 00:22:44.269 without new safety signals that did not

NOTE Confidence: 0.8144564045

00:22:44.269 --> 00:22:46.700 have an opportunity to include that here.

NOTE Confidence: 0.8144564045

00:22:46.700 --> 00:22:48.812 But most adverse adverse events were

NOTE Confidence: 0.8144564045

00:22:48.812 --> 00:22:50.999 reported as quote mild to moderate.

NOTE Confidence: 0.8144564045

00:22:51.000 --> 00:22:53.868 And finally the open label extension

NOTE Confidence: 0.8144564045

00:22:53.868 --> 00:22:55.780 period is ongoing currently.

NOTE Confidence: 0.8144564045

00:22:55.780 --> 00:22:58.324 Now to wrap up this little portion with

NOTE Confidence: 0.8144564045

00:22:58.324 --> 00:23:00.853 a third abstract from the Cleveland

NOTE Confidence: 0.8144564045

00:23:00.853 --> 00:23:03.577 Clinic of 300 plus consecutive patients

NOTE Confidence: 0.8144564045

00:23:03.651 --> 00:23:06.495 treated with splenectomy for a variety

NOTE Confidence: 0.8144564045

00:23:06.495 --> 00:23:08.391 of different immune cytopenias.

NOTE Confidence: 0.8144564045

00:23:08.400 --> 00:23:10.476 So the investigators here wanted to

NOTE Confidence: 0.8144564045

00:23:10.476 --> 00:23:12.328 identify whether they could isolate

NOTE Confidence: 0.8144564045

00:23:12.328 --> 00:23:14.388 risk factors that could potentially

NOTE Confidence: 0.8144564045

00:23:14.388 --> 00:23:16.476 predict response to splenectomy and

NOTE Confidence: 0.8144564045

00:23:16.476 --> 00:23:18.396 adult patients with immune cytopenias.

NOTE Confidence: 0.8144564045

00:23:18.400 --> 00:23:19.339 On the right,

NOTE Confidence: 0.8144564045

00:23:19.339 --> 00:23:21.530 you see a schematic of total splenectomy

NOTE Confidence: 0.8144564045

00:23:21.595 --> 00:23:23.407 cases that they reviewed over the

NOTE Confidence: 0.8144564045

00:23:23.407 --> 00:23:25.718 course of 20 years from 2000 to 2020.

NOTE Confidence: 0.8144564045

00:23:25.720 --> 00:23:28.090 And here you had 1800 patients.

NOTE Confidence: 0.8144564045

00:23:28.090 --> 00:23:29.987 There was a bunch of patients excluded

NOTE Confidence: 0.8144564045

00:23:29.987 --> 00:23:32.296 as they were trying to hone in on

NOTE Confidence: 0.8144564045

00:23:32.296 --> 00:23:33.444 cytopenias and then ultimately

NOTE Confidence: 0.8144564045

00:23:33.444 --> 00:23:34.749 on immune cytopenias.

NOTE Confidence: 0.8144564045

00:23:34.750 --> 00:23:36.178 And at the very bottom I circled

NOTE Confidence: 0.8144564045

00:23:36.178 --> 00:23:36.790 for urine red.

NOTE Confidence: 0.8144564045

00:23:36.790 --> 00:23:38.872 You can see what the diagnosis

NOTE Confidence: 0.8144564045

00:23:38.872 --> 00:23:40.570 were that they considered ITP,

NOTE Confidence: 0.8144564045

00:23:40.570 --> 00:23:41.968 autoimmune hemolytic anemia,

NOTE Confidence: 0.8144564045

00:23:41.968 --> 00:23:44.298 Evans syndrome and autoimmune neutropenia,

NOTE Confidence: 0.8144564045

00:23:44.300 --> 00:23:46.244 neutropenia in general.

NOTE Confidence: 0.8144564045

00:23:46.244 --> 00:23:49.484 This was a retrospective study,

NOTE Confidence: 0.8144564045

00:23:49.490 --> 00:23:52.508 339 patients and the majority were

NOTE Confidence: 0.8144564045

00:23:52.508 --> 00:23:55.160 ITP and autoimmune hemolytic anemia.

NOTE Confidence: 0.8144564045

00:23:55.160 --> 00:23:57.316 Their results are are a little bit

NOTE Confidence: 0.8144564045

00:23:57.316 --> 00:23:59.221 remarkable even for the fact that

NOTE Confidence: 0.8144564045

00:23:59.221 --> 00:24:01.069 this is retrospective study and here

NOTE Confidence: 0.8144564045

00:24:01.069 --> 00:24:03.399 you can see ITP autoimmune hemolytic

NOTE Confidence: 0.8144564045

00:24:03.399 --> 00:24:04.971 anemia and autoimmune neutropenia

NOTE Confidence: 0.8144564045

00:24:04.971 --> 00:24:07.010 at the very least being presented

NOTE Confidence: 0.8144564045

00:24:07.010 --> 00:24:09.140 and simple pie charts for having

NOTE Confidence: 0.8144564045

00:24:09.140 --> 00:24:11.285 complete versus partial versus no

NOTE Confidence: 0.8144564045

00:24:11.285 --> 00:24:12.572 responses to splenectomy.

NOTE Confidence: 0.8144564045

00:24:12.580 --> 00:24:15.055 And at the bottom you actually also see how

NOTE Confidence: 0.8144564045

00:24:15.055 --> 00:24:17.340 fast those responses occurred in weeks.

NOTE Confidence: 0.8144564045

00:24:17.340 --> 00:24:19.602 The overall response for all patients
NOTE Confidence: 0.8144564045

00:24:19.602 --> 00:24:22.300 with 74% complete response rate of
NOTE Confidence: 0.8144564045

00:24:22.300 --> 00:24:25.299 86 and a partial response of 14%.
NOTE Confidence: 0.8144564045

00:24:25.299 --> 00:24:26.556 In these patients,
NOTE Confidence: 0.8144564045

00:24:26.556 --> 00:24:29.070 but perhaps the bigger take home
NOTE Confidence: 0.8144564045

00:24:29.144 --> 00:24:30.940 point was the following.
NOTE Confidence: 0.8144564045

00:24:30.940 --> 00:24:33.082 And one out of five cases there
NOTE Confidence: 0.8144564045

00:24:33.082 --> 00:24:34.764 was a discordant diagnosis from
NOTE Confidence: 0.8144564045

00:24:34.764 --> 00:24:37.193 pre to post operation on the left.
NOTE Confidence: 0.8144564045

00:24:37.200 --> 00:24:38.904 In the left column you see
NOTE Confidence: 0.8144564045

00:24:38.904 --> 00:24:39.756 the splenectomy indication.
NOTE Confidence: 0.8144564045

00:24:39.760 --> 00:24:42.406 In the middle you see what the
NOTE Confidence: 0.8144564045

00:24:42.406 --> 00:24:43.540 actual postoperative pathologic
NOTE Confidence: 0.8567871172

00:24:43.601 --> 00:24:46.072 diagnosis was and the frequency of this
NOTE Confidence: 0.8567871172

00:24:46.072 --> 00:24:48.539 occurring in total to be exactly was 19%.
NOTE Confidence: 0.8567871172

00:24:48.540 --> 00:24:50.934 So 19% of patients were discordant

NOTE Confidence: 0.8567871172

00:24:50.934 --> 00:24:53.356 from pre to post operative

NOTE Confidence: 0.8567871172

00:24:53.356 --> 00:24:55.716 diagnosis again in these 300.

NOTE Confidence: 0.8567871172

00:24:55.716 --> 00:24:57.332 Ask consecutively treated patients

NOTE Confidence: 0.8567871172

00:24:57.332 --> 00:24:59.884 over the course of 2000 to 2020

NOTE Confidence: 0.8567871172

00:24:59.884 --> 00:25:02.070 twenty years in the Cleveland Clinic.

NOTE Confidence: 0.8567871172

00:25:02.070 --> 00:25:04.694 And to wrap up with one final take

NOTE Confidence: 0.8567871172

00:25:04.694 --> 00:25:07.252 home is the investigators did try

NOTE Confidence: 0.8567871172

00:25:07.252 --> 00:25:09.976 to isolate the risk factors that

NOTE Confidence: 0.8567871172

00:25:10.056 --> 00:25:12.851 could predict response versus not

NOTE Confidence: 0.8567871172

00:25:12.851 --> 00:25:14.998 predict response and these are being

NOTE Confidence: 0.8567871172

00:25:14.998 --> 00:25:16.540 parsed out further as I understand

NOTE Confidence: 0.8567871172

00:25:16.591 --> 00:25:18.041 in the actual manuscript that's

NOTE Confidence: 0.8567871172

00:25:18.041 --> 00:25:19.491 being written up and probably

NOTE Confidence: 0.8567871172

00:25:19.546 --> 00:25:21.306 published in the next 6 to 12 months.

NOTE Confidence: 0.8567871172

00:25:21.310 --> 00:25:23.389 But the big take home points here,

NOTE Confidence: 0.8567871172

00:25:23.390 --> 00:25:25.400 most of these are crossing
NOTE Confidence: 0.8567871172

00:25:25.400 --> 00:25:27.410 your odds ratio of 1,
NOTE Confidence: 0.8567871172

00:25:27.410 --> 00:25:30.476 but you'll see that young age in particular
NOTE Confidence: 0.8567871172

00:25:30.476 --> 00:25:32.660 age less than 40 years seem to predict.
NOTE Confidence: 0.8567871172

00:25:32.660 --> 00:25:34.495 Their response to splenectomy as
NOTE Confidence: 0.8567871172

00:25:34.495 --> 00:25:37.197 well as primary ITP also seemed to
NOTE Confidence: 0.8567871172

00:25:37.197 --> 00:25:39.192 predict for favorable response to
NOTE Confidence: 0.8567871172

00:25:39.192 --> 00:25:41.749 splenectomy on the converse side of it,
NOTE Confidence: 0.8567871172

00:25:41.750 --> 00:25:43.950 requiring multiple therapies predicted
NOTE Confidence: 0.8567871172

00:25:43.950 --> 00:25:46.700 for poor response to splenectomy.
NOTE Confidence: 0.8567871172

00:25:46.700 --> 00:25:47.645 So take homes.
NOTE Confidence: 0.8567871172

00:25:47.645 --> 00:25:49.220 From the studies that splenectomy
NOTE Confidence: 0.8567871172

00:25:49.220 --> 00:25:50.780 remains a valuable option,
NOTE Confidence: 0.8567871172

00:25:50.780 --> 00:25:52.930 specifically in patients whose values
NOTE Confidence: 0.8567871172

00:25:52.930 --> 00:25:55.080 and preferences align with surgery.
NOTE Confidence: 0.8567871172

00:25:55.080 --> 00:25:58.116 And there's a surprisingly high proportion,

NOTE Confidence: 0.8567871172

00:25:58.120 --> 00:26:02.150 one out of five that had an added value of

NOTE Confidence: 0.8567871172

00:26:02.253 --> 00:26:06.135 the diagnostic component in their course.

NOTE Confidence: 0.8567871172

00:26:06.135 --> 00:26:08.235 And so with that,

NOTE Confidence: 0.8567871172

00:26:08.240 --> 00:26:10.418 I want to say thank you and I'm going

NOTE Confidence: 0.8567871172

00:26:10.418 --> 00:26:12.728 to transition over to Doctor Sharda.

NOTE Confidence: 0.89827398

00:26:19.660 --> 00:26:20.659 Thank you, George.

NOTE Confidence: 0.871566085714286

00:26:23.520 --> 00:26:26.397 I have nothing to disclose as well.

NOTE Confidence: 0.871566085714286

00:26:26.400 --> 00:26:30.096 I will mostly be concentrating on

NOTE Confidence: 0.871566085714286

00:26:30.100 --> 00:26:32.460 some abstracts, interesting abstracts

NOTE Confidence: 0.871566085714286

00:26:32.460 --> 00:26:36.000 in the thrombosis realm and mostly

NOTE Confidence: 0.871566085714286

00:26:36.083 --> 00:26:38.459 cancer associated thrombosis.

NOTE Confidence: 0.871566085714286

00:26:38.460 --> 00:26:41.292 The first one is the the catheter three

NOTE Confidence: 0.871566085714286

00:26:41.292 --> 00:26:43.878 study which was a prospective study of

NOTE Confidence: 0.871566085714286

00:26:43.880 --> 00:26:46.690 apixaban for central venous catheter,

NOTE Confidence: 0.871566085714286

00:26:46.690 --> 00:26:48.709 associated upper extremity,

NOTE Confidence: 0.871566085714286

00:26:48.709 --> 00:26:52.074 venous thromboembolism and cancer patients.

NOTE Confidence: 0.871566085714286

00:26:52.080 --> 00:26:55.383 And this was, this comes from at

NOTE Confidence: 0.871566085714286

00:26:55.383 --> 00:26:58.048 least three senators in Canada.

NOTE Confidence: 0.871566085714286

00:26:58.050 --> 00:27:01.809 So this was a a multi center

NOTE Confidence: 0.871566085714286

00:27:01.809 --> 00:27:03.750 prospective cohort study.

NOTE Confidence: 0.6957774275

00:27:06.730 --> 00:27:10.522 In patients with CVC associated upper

NOTE Confidence: 0.6957774275

00:27:10.522 --> 00:27:14.509 extremity DVT they were treated with.

NOTE Confidence: 0.6957774275

00:27:14.510 --> 00:27:16.892 On a low molecular weight heparin

NOTE Confidence: 0.6957774275

00:27:16.892 --> 00:27:19.582 dalteparin in their case for seven days

NOTE Confidence: 0.6957774275

00:27:19.582 --> 00:27:22.402 followed by a full dose of apixaban for

NOTE Confidence: 0.6957774275

00:27:22.402 --> 00:27:25.194 11 weeks and and and the patients were

NOTE Confidence: 0.6957774275

00:27:25.194 --> 00:27:28.466 followed for for at least 12 weeks.

NOTE Confidence: 0.6957774275

00:27:28.470 --> 00:27:31.356 The inclusion criteria was all adults

NOTE Confidence: 0.6957774275

00:27:31.356 --> 00:27:33.873 with with active malignancy and

NOTE Confidence: 0.6957774275

00:27:33.873 --> 00:27:36.463 and clinically significant that is

NOTE Confidence: 0.6957774275

00:27:36.463 --> 00:27:38.979 symptomatic upper extremity DVT in

NOTE Confidence: 0.6957774275

00:27:38.979 --> 00:27:41.199 association with the counter a CVC

NOTE Confidence: 0.6957774275

00:27:41.199 --> 00:27:43.906 and the main exclusion criteria were.

NOTE Confidence: 0.6957774275

00:27:43.906 --> 00:27:47.098 Patients with active bleeding or clip

NOTE Confidence: 0.6957774275

00:27:47.098 --> 00:27:51.018 bits less than 75 or a need for dual

NOTE Confidence: 0.6957774275

00:27:51.018 --> 00:27:53.191 antiplatelet therapy as well as most

NOTE Confidence: 0.6957774275

00:27:53.191 --> 00:27:55.546 of the patients with hematologic

NOTE Confidence: 0.6957774275

00:27:55.546 --> 00:27:58.417 malignancies or planned for stem cell

NOTE Confidence: 0.6957774275

00:27:58.417 --> 00:28:01.135 transplant as well as pulmonary embolism

NOTE Confidence: 0.6957774275

00:28:01.140 --> 00:28:05.310 with only with hemodynamic instability.

NOTE Confidence: 0.788521326666667

00:28:07.560 --> 00:28:10.986 The primary outcome was catheter survival

NOTE Confidence: 0.788521326666667

00:28:10.986 --> 00:28:14.299 at three months and the secondary

NOTE Confidence: 0.788521326666667

00:28:14.299 --> 00:28:17.497 outcomes were any types of symptomatic

NOTE Confidence: 0.788521326666667

00:28:17.497 --> 00:28:20.272 recurrent venous thromboembolism as

NOTE Confidence: 0.788521326666667

00:28:20.272 --> 00:28:22.876 well as bleeding both major as well

NOTE Confidence: 0.788521326666667

00:28:22.876 --> 00:28:24.958 as clinically relevant non major

NOTE Confidence: 0.788521326666667

00:28:24.958 --> 00:28:27.484 bleeds and deaths from any causes.

NOTE Confidence: 0.788521326666667

00:28:27.490 --> 00:28:33.458 Umm, so here on the the

NOTE Confidence: 0.788521326666667

00:28:33.458 --> 00:28:35.066 patients demographics here,

NOTE Confidence: 0.788521326666667

00:28:35.070 --> 00:28:37.968 the 70 patients from 3 senators

NOTE Confidence: 0.788521326666667

00:28:37.970 --> 00:28:40.370 majority were female, about 60%.

NOTE Confidence: 0.788521326666667

00:28:40.370 --> 00:28:41.759 Median age 62.

NOTE Confidence: 0.842329573

00:28:43.790 --> 00:28:46.022 The diagnostic modality used

NOTE Confidence: 0.842329573

00:28:46.022 --> 00:28:48.812 in most patients were Doppler

NOTE Confidence: 0.842329573

00:28:48.812 --> 00:28:50.650 ultrasounds and as you can see

NOTE Confidence: 0.842329573

00:28:50.650 --> 00:28:51.674 these are symptomatic events.

NOTE Confidence: 0.842329573

00:28:51.680 --> 00:28:54.866 So almost 75% of the patients

NOTE Confidence: 0.842329573

00:28:54.866 --> 00:28:56.990 actually have proximal upper

NOTE Confidence: 0.842329573

00:28:57.085 --> 00:28:59.833 extremity DVT involving subclavian,

NOTE Confidence: 0.842329573

00:28:59.833 --> 00:29:02.397 at least subclavian veins.

NOTE Confidence: 0.896160464444444

00:29:04.590 --> 00:29:06.230 And this is perhaps slightly

NOTE Confidence: 0.896160464444444

00:29:06.230 --> 00:29:07.542 different from our practice,

NOTE Confidence: 0.896160464444444

00:29:07.550 --> 00:29:09.206 so about 80% of the patients.

NOTE Confidence: 0.896160464444444

00:29:09.210 --> 00:29:12.330 So these were mostly outpatient.

NOTE Confidence: 0.896160464444444

00:29:12.330 --> 00:29:14.120 The patients being treated outpatients

NOTE Confidence: 0.896160464444444

00:29:14.120 --> 00:29:17.420 and and about 80% of them had picks

NOTE Confidence: 0.896160464444444

00:29:17.420 --> 00:29:20.096 and only 20% had portacaths and as

NOTE Confidence: 0.896160464444444

00:29:20.096 --> 00:29:22.779 you can see the type of cancer about

NOTE Confidence: 0.896160464444444

00:29:22.779 --> 00:29:25.555 a third were breast and a third were

NOTE Confidence: 0.896160464444444

00:29:25.635 --> 00:29:28.185 colon and the remaining were others.

NOTE Confidence: 0.896160464444444

00:29:28.190 --> 00:29:30.068 So coming to the primary outcome,

NOTE Confidence: 0.896160464444444

00:29:30.070 --> 00:29:34.036 so catheter survival so adds 12 weeks,

NOTE Confidence: 0.896160464444444

00:29:34.036 --> 00:29:39.332 40 patients had so which is about 5760%

NOTE Confidence: 0.896160464444444

00:29:39.332 --> 00:29:44.504 had catheter still present and functioning.

NOTE Confidence: 0.896160464444444

00:29:44.510 --> 00:29:48.731 But if you can see the reason for removal

NOTE Confidence: 0.896160464444444

00:29:48.731 --> 00:29:51.590 actually most of the patients who had

NOTE Confidence: 0.896160464444444

00:29:51.590 --> 00:29:54.886 it removed was because of end of the

NOTE Confidence: 0.896160464444444

00:29:54.886 --> 00:29:57.190 therapeutic need which is about 20.
NOTE Confidence: 0.8961604644444444

00:29:57.190 --> 00:30:00.006 One patients or 30% and then a minor
NOTE Confidence: 0.8961604644444444

00:30:00.006 --> 00:30:01.922 proportion of the patients with
NOTE Confidence: 0.8961604644444444

00:30:01.922 --> 00:30:04.582 with other reasons which is you know
NOTE Confidence: 0.8961604644444444

00:30:04.655 --> 00:30:07.103 infection or two patients died and
NOTE Confidence: 0.8961604644444444

00:30:07.103 --> 00:30:11.419 there were no recurrent events and so.
NOTE Confidence: 0.8961604644444444

00:30:11.420 --> 00:30:14.138 If you consider.
NOTE Confidence: 0.8961604644444444

00:30:14.140 --> 00:30:16.268 Or exclude the end of therapeutic needs.
NOTE Confidence: 0.8961604644444444

00:30:16.270 --> 00:30:18.140 The the catheter survival was
NOTE Confidence: 0.8961604644444444

00:30:18.140 --> 00:30:21.798 almost 100% with the pixman therapy.
NOTE Confidence: 0.8961604644444444

00:30:21.800 --> 00:30:24.278 The safety outcomes only one patient
NOTE Confidence: 0.8961604644444444

00:30:24.278 --> 00:30:27.258 had a recurrent DVT and the same arm,
NOTE Confidence: 0.8961604644444444

00:30:27.260 --> 00:30:30.100 and even in this patient the the line
NOTE Confidence: 0.8961604644444444

00:30:30.100 --> 00:30:33.176 was not removed and was a functional.
NOTE Confidence: 0.8961604644444444

00:30:33.180 --> 00:30:35.908 There were twelve bleeds,
NOTE Confidence: 0.8961604644444444

00:30:35.908 --> 00:30:40.136 six major and six minor bleeds

NOTE Confidence: 0.896160464444444

00:30:40.136 --> 00:30:43.313 and most happened within the first

NOTE Confidence: 0.896160464444444

00:30:43.313 --> 00:30:44.868 two months of of treatment.

NOTE Confidence: 0.896160464444444

00:30:44.870 --> 00:30:46.725 There were two deaths and they were

NOTE Confidence: 0.896160464444444

00:30:46.725 --> 00:30:51.160 both delayed and and cancer related.

NOTE Confidence: 0.896160464444444

00:30:51.160 --> 00:30:54.730 So limitations of course it's a single

NOTE Confidence: 0.896160464444444

00:30:54.730 --> 00:30:57.814 arm and most of the patients were

NOTE Confidence: 0.896160464444444

00:30:57.814 --> 00:31:00.663 outpatients and so perhaps not as ill

NOTE Confidence: 0.896160464444444

00:31:00.663 --> 00:31:03.127 and with the limited follow but but

NOTE Confidence: 0.896160464444444

00:31:03.209 --> 00:31:05.905 I I guess for our our practice many

NOTE Confidence: 0.896160464444444

00:31:05.905 --> 00:31:08.760 of these or most of these patients

NOTE Confidence: 0.896160464444444

00:31:08.760 --> 00:31:10.940 actually had picks our patient

NOTE Confidence: 0.896160464444444

00:31:11.021 --> 00:31:13.277 as compared to a Porter cats.

NOTE Confidence: 0.896160464444444

00:31:13.280 --> 00:31:15.830 So the conclusions were that the

NOTE Confidence: 0.896160464444444

00:31:15.830 --> 00:31:18.198 pixabaj should promise in treating

NOTE Confidence: 0.896160464444444

00:31:18.198 --> 00:31:20.546 central venous catheter associated

NOTE Confidence: 0.896160464444444

00:31:20.546 --> 00:31:22.307 upper extremity DVT.
NOTE Confidence: 0.8961604644444444

00:31:22.310 --> 00:31:24.605 And the observed bleeding rates
NOTE Confidence: 0.8961604644444444

00:31:24.605 --> 00:31:26.900 were lower than as previously
NOTE Confidence: 0.8961604644444444

00:31:26.900 --> 00:31:30.020 described with rivaroxaban.
NOTE Confidence: 0.8961604644444444

00:31:30.020 --> 00:31:34.835 And so here are the the other two studies.
NOTE Confidence: 0.8961604644444444

00:31:34.840 --> 00:31:36.178 Done previously by the same group.
NOTE Confidence: 0.8961604644444444

00:31:36.180 --> 00:31:38.714 So the first one was the catheter
NOTE Confidence: 0.8961604644444444

00:31:38.714 --> 00:31:40.572 study which was low molecular
NOTE Confidence: 0.8961604644444444

00:31:40.572 --> 00:31:42.565 weight heparin followed by widening
NOTE Confidence: 0.8961604644444444

00:31:42.565 --> 00:31:45.055 the antagonist and then the more
NOTE Confidence: 0.8961604644444444

00:31:45.055 --> 00:31:47.739 recent one was a catheter 2 which
NOTE Confidence: 0.8961604644444444

00:31:47.739 --> 00:31:49.990 was River rockband without a lead
NOTE Confidence: 0.8961604644444444

00:31:49.990 --> 00:31:52.114 in with the loonie weight heparin.
NOTE Confidence: 0.8961604644444444

00:31:52.120 --> 00:31:54.080 And here as you can see there are
NOTE Confidence: 0.8961604644444444

00:31:54.080 --> 00:31:56.521 a lot more bleeds and then the the
NOTE Confidence: 0.8961604644444444

00:31:56.521 --> 00:31:58.248 the current bonus the dalteparin

NOTE Confidence: 0.896160464444444

00:31:58.248 --> 00:32:00.884 followed by Pixar ban with perhaps

NOTE Confidence: 0.896160464444444

00:32:00.884 --> 00:32:02.420 with less Pittsburgh.

NOTE Confidence: 0.896160464444444

00:32:02.420 --> 00:32:04.922 I think the most important point is that in.

NOTE Confidence: 0.896160464444444

00:32:04.930 --> 00:32:07.210 In most of these patients,

NOTE Confidence: 0.896160464444444

00:32:07.210 --> 00:32:10.058 despite proximal and symptomatic

NOTE Confidence: 0.896160464444444

00:32:10.058 --> 00:32:14.330 upper extremity DVT's are the lines

NOTE Confidence: 0.896160464444444

00:32:14.436 --> 00:32:17.784 were not removed and and were not

NOTE Confidence: 0.896160464444444

00:32:17.784 --> 00:32:19.874 associated with infusion failure and

NOTE Confidence: 0.896160464444444

00:32:19.874 --> 00:32:22.486 and the lines were were were able

NOTE Confidence: 0.896160464444444

00:32:22.486 --> 00:32:27.260 to be saved with anticoagulation.

NOTE Confidence: 0.896160464444444

00:32:27.260 --> 00:32:30.426 So coming to the second one which

NOTE Confidence: 0.896160464444444

00:32:30.426 --> 00:32:32.610 is abstract #519 and

NOTE Confidence: 0.839978205185185

00:32:34.800 --> 00:32:36.781 the title of the abstract is only

NOTE Confidence: 0.839978205185185

00:32:36.781 --> 00:32:38.963 dynamics of C reactive protein to

NOTE Confidence: 0.839978205185185

00:32:38.963 --> 00:32:41.073 predict risk of venous thromboembolism

NOTE Confidence: 0.839978205185185

00:32:41.073 --> 00:32:43.376 in patients with cancer treated
NOTE Confidence: 0.839978205185185

00:32:43.376 --> 00:32:45.236 with immune checkpoint inhibitors.
NOTE Confidence: 0.839978205185185

00:32:45.240 --> 00:32:49.305 And this comes from Austria, Vienna,
NOTE Confidence: 0.839978205185185

00:32:49.305 --> 00:32:54.480 Austria. So just to be quick,
NOTE Confidence: 0.839978205185185

00:32:54.480 --> 00:32:57.260 because I'm an embolism.
NOTE Confidence: 0.839978205185185

00:32:57.260 --> 00:33:00.711 Is being recognized as a major complication
NOTE Confidence: 0.839978205185185

00:33:00.711 --> 00:33:03.660 of immune checkpoint inhibitor therapy.
NOTE Confidence: 0.839978205185185

00:33:03.660 --> 00:33:05.760 The rates have been described as
NOTE Confidence: 0.839978205185185

00:33:05.760 --> 00:33:09.050 high as 25% but the the prothrombin
NOTE Confidence: 0.839978205185185

00:33:09.050 --> 00:33:11.640 prothrombotic effect is the these
NOTE Confidence: 0.839978205185185

00:33:11.730 --> 00:33:13.634 immune checkpoint inhibitors as
NOTE Confidence: 0.839978205185185

00:33:13.634 --> 00:33:17.667 well as the the the risk factors are
NOTE Confidence: 0.839978205185185

00:33:17.667 --> 00:33:20.397 unclear because the risk factors,
NOTE Confidence: 0.839978205185185

00:33:20.400 --> 00:33:22.230 the traditional risk factors and the
NOTE Confidence: 0.839978205185185

00:33:22.230 --> 00:33:24.380 scoring system such as the KORANA score,
NOTE Confidence: 0.839978205185185

00:33:24.380 --> 00:33:27.230 they do not function as well.

NOTE Confidence: 0.839978205185185
00:33:27.230 --> 00:33:31.058 In the setting of checkpoint inhibitors.
NOTE Confidence: 0.839978205185185
00:33:31.060 --> 00:33:33.348 So basically the goal of the study was
NOTE Confidence: 0.839978205185185
00:33:33.348 --> 00:33:35.403 to explore early dynamics of systemic
NOTE Confidence: 0.839978205185185
00:33:35.403 --> 00:33:38.031 CRP levels after initiation of the immune
NOTE Confidence: 0.839978205185185
00:33:38.031 --> 00:33:40.191 checkpoint habits for prediction of
NOTE Confidence: 0.839978205185185
00:33:40.191 --> 00:33:43.770 venous thromboembolism in these patients.
NOTE Confidence: 0.839978205185185
00:33:43.770 --> 00:33:46.518 And why CRP?
NOTE Confidence: 0.839978205185185
00:33:46.518 --> 00:33:50.984 Because CRP has been shown to be a
NOTE Confidence: 0.839978205185185
00:33:50.984 --> 00:33:53.801 predictor of poorer outcome or higher
NOTE Confidence: 0.839978205185185
00:33:53.801 --> 00:33:58.130 designed CRP as well as a CRP response.
NOTE Confidence: 0.839978205185185
00:33:58.130 --> 00:34:00.686 CRP Flair has been associated with
NOTE Confidence: 0.839978205185185
00:34:00.686 --> 00:34:03.140 poor outcomes in these patients.
NOTE Confidence: 0.839978205185185
00:34:03.140 --> 00:34:06.710 And and it's well recognized that the
NOTE Confidence: 0.839978205185185
00:34:06.710 --> 00:34:08.886 developer systemic antitumoral immune
NOTE Confidence: 0.839978205185185
00:34:08.886 --> 00:34:11.554 response associated with a major
NOTE Confidence: 0.839978205185185

00:34:11.554 --> 00:34:14.184 inflammatory response in which CRP
NOTE Confidence: 0.839978205185185

00:34:14.184 --> 00:34:17.504 has been shown to be a major marker.
NOTE Confidence: 0.839978205185185

00:34:17.510 --> 00:34:21.094 Umm. So the methods.
NOTE Confidence: 0.839978205185185

00:34:21.094 --> 00:34:23.602 So this was a retrospective cohort
NOTE Confidence: 0.839978205185185

00:34:23.602 --> 00:34:26.214 study of about 405 patients.
NOTE Confidence: 0.839978205185185

00:34:26.214 --> 00:34:29.999 These were patients with cancer
NOTE Confidence: 0.839978205185185

00:34:29.999 --> 00:34:34.708 treated in in in Med UNI Vienna.
NOTE Confidence: 0.839978205185185

00:34:34.710 --> 00:34:37.070 The.
NOTE Confidence: 0.839978205185185

00:34:37.070 --> 00:34:39.331 The follow-up was at least for the
NOTE Confidence: 0.839978205185185

00:34:39.331 --> 00:34:41.752 duration of IC ICI therapy until
NOTE Confidence: 0.839978205185185

00:34:41.752 --> 00:34:43.688 subsequent anti cancer therapy
NOTE Confidence: 0.839978205185185

00:34:43.688 --> 00:34:46.795 death or a maximum of three months
NOTE Confidence: 0.839978205185185

00:34:46.795 --> 00:34:49.808 of the last cycle of the immune
NOTE Confidence: 0.839978205185185

00:34:49.808 --> 00:34:52.068 checkpoint inhibitor therapy and
NOTE Confidence: 0.839978205185185

00:34:52.068 --> 00:34:57.260 and the endpoints were DTE.
NOTE Confidence: 0.839978205185185

00:34:57.260 --> 00:34:59.654 That were mostly pulmonary embolism and DVT,

NOTE Confidence: 0.839978205185185

00:34:59.660 --> 00:35:02.180 but also recorded for splanchnic,

NOTE Confidence: 0.839978205185185

00:35:02.180 --> 00:35:03.592 venous thrombosis,

NOTE Confidence: 0.839978205185185

00:35:03.592 --> 00:35:05.710 catheter related thrombosis

NOTE Confidence: 0.839978205185185

00:35:05.710 --> 00:35:08.534 and other other events.

NOTE Confidence: 0.839978205185185

00:35:08.540 --> 00:35:10.646 In terms of the CRP dynamics,

NOTE Confidence: 0.839978205185185

00:35:10.650 --> 00:35:14.208 the CRP was measured at baseline

NOTE Confidence: 0.839978205185185

00:35:14.210 --> 00:35:15.866 that is within the four weeks,

NOTE Confidence: 0.839978205185185

00:35:15.870 --> 00:35:18.035 within four weeks prior to

NOTE Confidence: 0.839978205185185

00:35:18.035 --> 00:35:20.748 institution of this therapy and then

NOTE Confidence: 0.839978205185185

00:35:20.748 --> 00:35:22.628 it was longitudinally monitored

NOTE Confidence: 0.839978205185185

00:35:22.628 --> 00:35:25.508 for the first three months after

NOTE Confidence: 0.839978205185185

00:35:25.508 --> 00:35:27.748 the initiation of the therapy.

NOTE Confidence: 0.839978205185185

00:35:27.750 --> 00:35:30.487 And for the purpose of this study

NOTE Confidence: 0.839978205185185

00:35:30.487 --> 00:35:33.122 this the the CRP dynamics were

NOTE Confidence: 0.839978205185185

00:35:33.122 --> 00:35:35.876 defined either as CRP flare which

NOTE Confidence: 0.839978205185185

00:35:35.876 --> 00:35:38.912 is increase in the CRP by by.
NOTE Confidence: 0.839978205185185

00:35:38.912 --> 00:35:42.780 At least 2.5 fold over the baseline
NOTE Confidence: 0.839978205185185

00:35:42.780 --> 00:35:46.350 or a CRP response which was 50%
NOTE Confidence: 0.839978205185185

00:35:46.350 --> 00:35:50.400 relative decrease from the baseline.
NOTE Confidence: 0.839978205185185

00:35:50.400 --> 00:35:52.830 Um.
NOTE Confidence: 0.839978205185185

00:35:52.830 --> 00:35:56.526 So the most important in terms of the
NOTE Confidence: 0.839978205185185

00:35:56.526 --> 00:35:59.043 cohort demographics is that most of
NOTE Confidence: 0.839978205185185

00:35:59.043 --> 00:36:04.400 the patients were staged for malignancies.
NOTE Confidence: 0.839978205185185

00:36:04.400 --> 00:36:06.638 Of of a variety of types,
NOTE Confidence: 0.839978205185185

00:36:06.640 --> 00:36:09.590 mostly therapies where are cancers
NOTE Confidence: 0.839978205185185

00:36:09.590 --> 00:36:14.035 known to be known to respond to to
NOTE Confidence: 0.839978205185185

00:36:14.035 --> 00:36:16.612 immune checkpoint inhibitors and then
NOTE Confidence: 0.839978205185185

00:36:16.612 --> 00:36:20.480 many of the patients had received or
NOTE Confidence: 0.839978205185185

00:36:20.480 --> 00:36:23.680 seen multiple lines of therapies.
NOTE Confidence: 0.839978205185185

00:36:23.680 --> 00:36:26.720 The the median follow up for the
NOTE Confidence: 0.839978205185185

00:36:26.720 --> 00:36:28.780 study for was about 8.5 months.

NOTE Confidence: 0.524805423333333

00:36:31.280 --> 00:36:35.918 Umm, so, so defining CRP flare.

NOTE Confidence: 0.524805423333333

00:36:35.920 --> 00:36:39.760 So among the 405 patients,

NOTE Confidence: 0.524805423333333

00:36:39.760 --> 00:36:41.310 70% had a CRP flare,

NOTE Confidence: 0.524805423333333

00:36:41.310 --> 00:36:45.441 which is again a rise in CRP of greater

NOTE Confidence: 0.524805423333333

00:36:45.441 --> 00:36:48.927 than 2.5 folds over the baseline.

NOTE Confidence: 0.524805423333333

00:36:48.930 --> 00:36:55.170 And then there, so let me so in

NOTE Confidence: 0.524805423333333

00:36:55.170 --> 00:36:58.434 terms of the different a definition,

NOTE Confidence: 0.524805423333333

00:36:58.434 --> 00:37:02.500 so basically some 78 to 80% had the

NOTE Confidence: 0.524805423333333

00:37:02.500 --> 00:37:06.346 CRP flare and then about a third had

NOTE Confidence: 0.524805423333333

00:37:06.346 --> 00:37:10.662 CRP response which is drop in CRP.

NOTE Confidence: 0.524805423333333

00:37:10.662 --> 00:37:17.010 Either after a flare or in about um.

NOTE Confidence: 0.524805423333333

00:37:17.010 --> 00:37:19.446 14% of the patients without a flare

NOTE Confidence: 0.524805423333333

00:37:19.446 --> 00:37:22.694 to to less than 50% of the baseline

NOTE Confidence: 0.524805423333333

00:37:22.694 --> 00:37:26.350 and then about 1/3 of the patients

NOTE Confidence: 0.524805423333333

00:37:26.350 --> 00:37:28.408 did not or were non responders which,

NOTE Confidence: 0.524805423333333

00:37:28.410 --> 00:37:30.542 which is their CRP,
NOTE Confidence: 0.524805423333333

00:37:30.542 --> 00:37:33.780 did not reduce to 50% of the baseline.
NOTE Confidence: 0.783852911428572

00:37:36.550 --> 00:37:40.806 And then based on the CRP dynamics,
NOTE Confidence: 0.783852911428572

00:37:40.810 --> 00:37:44.410 the the the authors found that the risk
NOTE Confidence: 0.783852911428572

00:37:44.410 --> 00:37:48.200 of DVT E the cumulative risk of DVT
NOTE Confidence: 0.783852911428572

00:37:48.200 --> 00:37:53.408 was about 3.5 fold in in patients who
NOTE Confidence: 0.783852911428572

00:37:53.408 --> 00:37:59.588 had a CRP flare irrespective of of.
NOTE Confidence: 0.783852911428572

00:37:59.590 --> 00:38:01.478 A response or not?
NOTE Confidence: 0.801023083181818

00:38:03.730 --> 00:38:04.600 More importantly,
NOTE Confidence: 0.801023083181818

00:38:04.600 --> 00:38:08.080 they also found that the the risk of
NOTE Confidence: 0.801023083181818

00:38:08.164 --> 00:38:11.158 DVT was associated with an increase
NOTE Confidence: 0.801023083181818

00:38:11.158 --> 00:38:14.050 mortality according to the CRP flare.
NOTE Confidence: 0.801023083181818

00:38:14.050 --> 00:38:17.370 So the hazard ratio for death after VE
NOTE Confidence: 0.801023083181818

00:38:17.370 --> 00:38:20.457 Justed for cancer type was about 3.5
NOTE Confidence: 0.801023083181818

00:38:20.457 --> 00:38:23.166 fold in patients with CRV CRV flare
NOTE Confidence: 0.801023083181818

00:38:23.166 --> 00:38:26.038 and then adjusted for the stage of

NOTE Confidence: 0.801023083181818

00:38:26.038 --> 00:38:32.450 the cancer was 3.21 fold again. Um.

NOTE Confidence: 0.720324951428571

00:38:34.910 --> 00:38:37.115 In patients with with their CRP flare.

NOTE Confidence: 0.82518405

00:38:39.760 --> 00:38:44.448 So the conclusions were that's the early

NOTE Confidence: 0.82518405

00:38:44.448 --> 00:38:47.309 dynamics of systemic CRP levels are

NOTE Confidence: 0.82518405

00:38:47.309 --> 00:38:50.333 associated with the risk of VTE during

NOTE Confidence: 0.82518405

00:38:50.333 --> 00:38:52.699 immune checkpoint inhibitor therapy and

NOTE Confidence: 0.82518405

00:38:52.699 --> 00:38:56.014 the highest risk of DVT was observed

NOTE Confidence: 0.82518405

00:38:56.014 --> 00:38:59.767 in patients with early CRP flare after

NOTE Confidence: 0.82518405

00:38:59.767 --> 00:39:03.596 ICI initiation and then the lowest risk

NOTE Confidence: 0.82518405

00:39:03.596 --> 00:39:07.740 was in patients where the CRP drop.

NOTE Confidence: 0.82518405

00:39:07.740 --> 00:39:10.435 Dropped below 50% with no prior flare,

NOTE Confidence: 0.82518405

00:39:10.440 --> 00:39:13.618 but this was a very small proportion

NOTE Confidence: 0.82518405

00:39:13.618 --> 00:39:15.908 of patients about 12 to 14%.

NOTE Confidence: 0.82518405

00:39:15.910 --> 00:39:18.774 And then they also found a potential risk,

NOTE Confidence: 0.82518405

00:39:18.780 --> 00:39:22.104 a link between immune checkpoint inhibitor

NOTE Confidence: 0.82518405

00:39:22.104 --> 00:39:24.320 induced systemic inflammatory response
NOTE Confidence: 0.82518405

00:39:24.393 --> 00:39:27.635 and risk of CTE in in addition to an
NOTE Confidence: 0.82518405

00:39:27.635 --> 00:39:30.387 independent association of of Vt with
NOTE Confidence: 0.82518405

00:39:30.387 --> 00:39:33.955 mortality in patients who have a CRP flair.
NOTE Confidence: 0.82518405

00:39:33.960 --> 00:39:35.766 So I think with this I'll end.
NOTE Confidence: 0.891980224

00:39:43.910 --> 00:39:44.768 Well, that's great.
NOTE Confidence: 0.891980224

00:39:44.768 --> 00:39:46.198 Thank you all for those
NOTE Confidence: 0.891980224

00:39:46.198 --> 00:39:46.770 great presentations.
NOTE Confidence: 0.891980224

00:39:46.770 --> 00:39:48.706 So thanks so much.
NOTE Confidence: 0.891980224

00:39:48.706 --> 00:39:51.126 I if people have questions,
NOTE Confidence: 0.891980224

00:39:51.130 --> 00:39:53.244 please put them in the Q&A or
NOTE Confidence: 0.891980224

00:39:53.244 --> 00:39:55.355 the chat and while we're waiting
NOTE Confidence: 0.891980224

00:39:55.355 --> 00:39:57.605 for them to come in perhaps
NOTE Confidence: 0.891980224

00:39:57.605 --> 00:39:59.708 some I can start with a few.
NOTE Confidence: 0.867096442857143

00:40:02.110 --> 00:40:03.958 If Doctor Van Doren is still on,
NOTE Confidence: 0.867096442857143

00:40:03.960 --> 00:40:04.842 and I know she might have

NOTE Confidence: 0.867096442857143
00:40:04.842 --> 00:40:05.730 had to go into clinic,
NOTE Confidence: 0.867096442857143
00:40:05.730 --> 00:40:07.470 looks like she did step off.
NOTE Confidence: 0.867096442857143
00:40:07.470 --> 00:40:11.043 So George, I I have a question for you.
NOTE Confidence: 0.867096442857143
00:40:11.050 --> 00:40:15.298 In the study with Subtitle MIB
NOTE Confidence: 0.867096442857143
00:40:15.298 --> 00:40:17.348 and cold agglutinin disease,
NOTE Confidence: 0.867096442857143
00:40:17.348 --> 00:40:20.470 you noted that there was an increase
NOTE Confidence: 0.867096442857143
00:40:20.470 --> 00:40:22.738 in patient reported outcomes.
NOTE Confidence: 0.867096442857143
00:40:22.738 --> 00:40:25.432 Quality of life improved despite
NOTE Confidence: 0.867096442857143
00:40:25.432 --> 00:40:27.542 the fact that these individuals
NOTE Confidence: 0.867096442857143
00:40:27.542 --> 00:40:30.210 did not require blood transfusions.
NOTE Confidence: 0.867096442857143
00:40:30.210 --> 00:40:31.968 Could you postulate on why they
NOTE Confidence: 0.867096442857143
00:40:31.968 --> 00:40:33.920 may have had this improvement?
NOTE Confidence: 0.867096442857143
00:40:33.920 --> 00:40:36.202 In the way they felt without having
NOTE Confidence: 0.867096442857143
00:40:36.202 --> 00:40:38.529 a need for blood transfusion.
NOTE Confidence: 0.803603747142857
00:40:39.210 --> 00:40:42.017 Thank you, Bob. Such a great question.
NOTE Confidence: 0.803603747142857

00:40:42.020 --> 00:40:44.150 There's a thud in the
NOTE Confidence: 0.803603747142857

00:40:44.150 --> 00:40:45.854 hemolytic community in general,
NOTE Confidence: 0.803603747142857

00:40:45.860 --> 00:40:47.904 both in autoimmune hemolytic anemia and PNH
NOTE Confidence: 0.803603747142857

00:40:47.904 --> 00:40:49.900 and other disorders where we see hemolysis,
NOTE Confidence: 0.803603747142857

00:40:49.900 --> 00:40:52.932 that quality of life is affected by the
NOTE Confidence: 0.803603747142857

00:40:52.932 --> 00:40:55.117 hemolysis independent of hemoglobin as well,
NOTE Confidence: 0.803603747142857

00:40:55.120 --> 00:40:57.868 in addition to hemoglobin drops and
NOTE Confidence: 0.803603747142857

00:40:57.868 --> 00:40:59.700 low hemoglobin hemoglobin levels.
NOTE Confidence: 0.803603747142857

00:40:59.700 --> 00:41:01.710 The idea being that in
NOTE Confidence: 0.803603747142857

00:41:01.710 --> 00:41:02.856 a chronically hemolytic,
NOTE Confidence: 0.803603747142857

00:41:02.856 --> 00:41:04.536 in a chronic hemolytic stage,
NOTE Confidence: 0.803603747142857

00:41:04.540 --> 00:41:05.995 you have an underlying degree
NOTE Confidence: 0.803603747142857

00:41:05.995 --> 00:41:06.577 of inflammation.
NOTE Confidence: 0.803603747142857

00:41:06.580 --> 00:41:08.506 At least that's the theory that's
NOTE Confidence: 0.803603747142857

00:41:08.506 --> 00:41:09.790 being posited that's contributing
NOTE Confidence: 0.803603747142857

00:41:09.840 --> 00:41:11.035 perhaps to this fatigue and

NOTE Confidence: 0.803603747142857
00:41:11.035 --> 00:41:12.620 the idea being that if we can.
NOTE Confidence: 0.803603747142857
00:41:12.620 --> 00:41:15.735 Shut down the hemolysis or maybe let's
NOTE Confidence: 0.803603747142857
00:41:15.735 --> 00:41:19.550 say decrease it with ages like symbolab,
NOTE Confidence: 0.803603747142857
00:41:19.550 --> 00:41:23.166 the monoclonal C1S antibody for cold
NOTE Confidence: 0.803603747142857
00:41:23.166 --> 00:41:26.134 agglutinin disease or anti C3 and C5
NOTE Confidence: 0.803603747142857
00:41:26.134 --> 00:41:28.330 therapies for example in pH that we
NOTE Confidence: 0.803603747142857
00:41:28.330 --> 00:41:30.436 can further improve quality of life.
NOTE Confidence: 0.803603747142857
00:41:30.440 --> 00:41:32.258 And I think this also underscores
NOTE Confidence: 0.803603747142857
00:41:32.258 --> 00:41:33.616 too that umm, you know,
NOTE Confidence: 0.803603747142857
00:41:33.616 --> 00:41:35.786 we we focus a lot in the past on
NOTE Confidence: 0.803603747142857
00:41:35.786 --> 00:41:37.742 these hard outcomes which are of
NOTE Confidence: 0.803603747142857
00:41:37.742 --> 00:41:39.410 course important like hemoglobin,
NOTE Confidence: 0.803603747142857
00:41:39.410 --> 00:41:41.500 but there's an additional component
NOTE Confidence: 0.803603747142857
00:41:41.500 --> 00:41:43.172 to quality of life.
NOTE Confidence: 0.803603747142857
00:41:43.180 --> 00:41:44.800 Beyond that now that is difficult
NOTE Confidence: 0.803603747142857

00:41:44.800 --> 00:41:46.868 to capture and I think that the
NOTE Confidence: 0.803603747142857

00:41:46.868 --> 00:41:48.408 investigators could have done a
NOTE Confidence: 0.803603747142857

00:41:48.408 --> 00:41:49.914 better job honestly with similar
NOTE Confidence: 0.803603747142857

00:41:49.914 --> 00:41:52.239 map and in fact most of phase three
NOTE Confidence: 0.803603747142857

00:41:52.239 --> 00:41:53.406 investigations currently looking
NOTE Confidence: 0.803603747142857

00:41:53.406 --> 00:41:55.740 at quality of life use patient
NOTE Confidence: 0.803603747142857

00:41:55.803 --> 00:41:57.608 reported outcomes which is good.
NOTE Confidence: 0.803603747142857

00:41:57.610 --> 00:42:00.060 But most of the times they're not
NOTE Confidence: 0.803603747142857

00:42:00.060 --> 00:42:01.252 validated externally validated.
NOTE Confidence: 0.803603747142857

00:42:01.252 --> 00:42:03.778 And the one for sure surefire
NOTE Confidence: 0.803603747142857

00:42:03.778 --> 00:42:06.370 way to robustly look at these,
NOTE Confidence: 0.803603747142857

00:42:06.370 --> 00:42:08.614 although that takes a little bit
NOTE Confidence: 0.803603747142857

00:42:08.614 --> 00:42:11.436 more money and effort is to actually
NOTE Confidence: 0.803603747142857

00:42:11.436 --> 00:42:13.516 measure quality of life directly.
NOTE Confidence: 0.803603747142857

00:42:13.520 --> 00:42:15.340 With direct patient interviews,
NOTE Confidence: 0.803603747142857

00:42:15.340 --> 00:42:18.460 that that's a conversation for another time.

NOTE Confidence: 0.803603747142857
00:42:18.460 --> 00:42:20.231 But that's a conversation I have had
NOTE Confidence: 0.803603747142857
00:42:20.231 --> 00:42:21.696 with colleagues in the BMT space
NOTE Confidence: 0.803603747142857
00:42:21.696 --> 00:42:23.236 and other spaces who want to truly
NOTE Confidence: 0.803603747142857
00:42:23.290 --> 00:42:24.898 capture the quality of life beyond,
NOTE Confidence: 0.803603747142857
00:42:24.900 --> 00:42:26.916 let's say like just the questionnaire stuff,
NOTE Confidence: 0.803603747142857
00:42:26.920 --> 00:42:28.020 12 or whatever it is.
NOTE Confidence: 0.857836389230769
00:42:29.040 --> 00:42:30.224 That's great. Thanks, George.
NOTE Confidence: 0.857836389230769
00:42:30.224 --> 00:42:32.422 I wonder if some of that could
NOTE Confidence: 0.857836389230769
00:42:32.422 --> 00:42:34.232 be applied to individuals who
NOTE Confidence: 0.857836389230769
00:42:34.232 --> 00:42:35.680 have non transfusion dependent
NOTE Confidence: 0.857836389230769
00:42:35.738 --> 00:42:37.766 thalassemia as well who have fatigue.
NOTE Confidence: 0.857836389230769
00:42:37.770 --> 00:42:41.118 That's really fascinating. Yeah.
NOTE Confidence: 0.857836389230769
00:42:41.120 --> 00:42:43.400 Anish, I I have a question for you if I may.
NOTE Confidence: 0.857836389230769
00:42:43.400 --> 00:42:46.060 So the the last abstract you presented
NOTE Confidence: 0.857836389230769
00:42:46.060 --> 00:42:49.438 with CRP and immune checkpoint inhibitors.
NOTE Confidence: 0.857836389230769

00:42:49.440 --> 00:42:52.536 You know, obviously if we were
NOTE Confidence: 0.857836389230769

00:42:52.536 --> 00:42:54.600 to intervene with prophylaxis,
NOTE Confidence: 0.857836389230769

00:42:54.600 --> 00:42:58.980 measuring CRP's would be.
NOTE Confidence: 0.857836389230769

00:42:58.980 --> 00:43:00.708 It would be too late in a sense,
NOTE Confidence: 0.857836389230769

00:43:00.710 --> 00:43:03.645 so you couldn't measure the
NOTE Confidence: 0.857836389230769

00:43:03.645 --> 00:43:06.580 CRP and then intervene with.
NOTE Confidence: 0.857836389230769

00:43:06.580 --> 00:43:07.612 With anticoagulant because
NOTE Confidence: 0.857836389230769

00:43:07.612 --> 00:43:09.676 it would be after the fact.
NOTE Confidence: 0.857836389230769

00:43:09.680 --> 00:43:11.176 So my question is,
NOTE Confidence: 0.857836389230769

00:43:11.176 --> 00:43:13.046 are the CRP changes similar
NOTE Confidence: 0.857836389230769

00:43:13.046 --> 00:43:14.600 from cycle to cycle?
NOTE Confidence: 0.857836389230769

00:43:14.600 --> 00:43:17.525 So can you use a cycle of CRP and
NOTE Confidence: 0.857836389230769

00:43:17.525 --> 00:43:20.109 anticipate that in the next cycle
NOTE Confidence: 0.857836389230769

00:43:20.109 --> 00:43:21.853 of immune checkpoint inhibitors
NOTE Confidence: 0.857836389230769

00:43:21.853 --> 00:43:24.656 that change in CRP will be the same?
NOTE Confidence: 0.89731385

00:43:28.030 --> 00:43:29.696 I think it's a very good question.

NOTE Confidence: 0.7843728

00:43:32.140 --> 00:43:34.890 You know, if the majority of the patients,

NOTE Confidence: 0.7843728

00:43:34.890 --> 00:43:43.479 about 7080% had a CRP flare and so my.

NOTE Confidence: 0.7843728

00:43:43.480 --> 00:43:45.232 And and so and.

NOTE Confidence: 0.7843728

00:43:45.232 --> 00:43:47.422 These were the group with.

NOTE Confidence: 0.7843728

00:43:47.430 --> 00:43:49.710 With irrespective of whether

NOTE Confidence: 0.7843728

00:43:49.710 --> 00:43:51.990 they had a response,

NOTE Confidence: 0.7843728

00:43:51.990 --> 00:43:56.086 you know and you know they halved their

NOTE Confidence: 0.7843728

00:43:56.086 --> 00:43:58.813 CRP irrespective of that they were

NOTE Confidence: 0.7843728

00:43:58.813 --> 00:44:02.967 they were at high risk for for events and so.

NOTE Confidence: 0.7843728

00:44:02.970 --> 00:44:07.836 Although it's a very interesting observation,

NOTE Confidence: 0.7843728

00:44:07.840 --> 00:44:09.568 and you know this question comes,

NOTE Confidence: 0.7843728

00:44:09.570 --> 00:44:12.498 it's coming up more and more.

NOTE Confidence: 0.7843728

00:44:12.500 --> 00:44:16.195 It's it's again you know 80% of the of the

NOTE Confidence: 0.7843728

00:44:16.195 --> 00:44:19.348 patients who are at risk and so it's it's.

NOTE Confidence: 0.7843728

00:44:19.350 --> 00:44:23.976 It's again a major, it's a.

NOTE Confidence: 0.7843728

00:44:23.980 --> 00:44:26.416 It I think the this whole,
NOTE Confidence: 0.7843728

00:44:26.420 --> 00:44:27.884 this whole, you know,
NOTE Confidence: 0.7843728

00:44:27.884 --> 00:44:30.780 CRP as a marker of inflammatory response.
NOTE Confidence: 0.842828760769231

00:44:33.240 --> 00:44:35.720 As a marker for VTE in these patients
NOTE Confidence: 0.842828760769231

00:44:35.720 --> 00:44:38.399 in this group will have to be refined
NOTE Confidence: 0.842828760769231

00:44:38.399 --> 00:44:40.931 a little more just because you know
NOTE Confidence: 0.842828760769231

00:44:40.931 --> 00:44:43.474 they're just the 80% eighty 85% of
NOTE Confidence: 0.842828760769231

00:44:43.474 --> 00:44:45.580 the patients are at they're claiming
NOTE Confidence: 0.842828760769231

00:44:45.651 --> 00:44:48.059 or at high risk which does not really
NOTE Confidence: 0.842828760769231

00:44:48.060 --> 00:44:51.508 help us that much if I didn't answer
NOTE Confidence: 0.842828760769231

00:44:51.508 --> 00:44:52.888 your question directly but that's
NOTE Confidence: 0.842828760769231

00:44:52.888 --> 00:44:54.836 what came to my mind and like you
NOTE Confidence: 0.842828760769231

00:44:54.836 --> 00:44:56.258 know again yes it's interesting but
NOTE Confidence: 0.842828760769231

00:44:56.258 --> 00:44:57.767 it's you know you're you're telling
NOTE Confidence: 0.842828760769231

00:44:57.767 --> 00:44:59.585 me that most of the patients are
NOTE Confidence: 0.842828760769231

00:44:59.585 --> 00:45:01.930 at high risk so so you know

NOTE Confidence: 0.770090885555556
00:45:02.880 --> 00:45:03.489 so there's a.
NOTE Confidence: 0.770090885555556
00:45:03.489 --> 00:45:04.707 Question that came in the chat,
NOTE Confidence: 0.770090885555556
00:45:04.710 --> 00:45:06.975 the question and answer extending
NOTE Confidence: 0.770090885555556
00:45:06.975 --> 00:45:10.243 this and the the question was are
NOTE Confidence: 0.770090885555556
00:45:10.243 --> 00:45:12.548 there recommendations that do CRP
NOTE Confidence: 0.770090885555556
00:45:12.548 --> 00:45:14.546 levels prior to immunotherapy and
NOTE Confidence: 0.770090885555556
00:45:14.546 --> 00:45:16.850 then monitor them on a monthly
NOTE Confidence: 0.770090885555556
00:45:16.920 --> 00:45:19.041 basis and is there any role at
NOTE Confidence: 0.770090885555556
00:45:19.041 --> 00:45:21.411 this point for prophylaxis and the
NOTE Confidence: 0.770090885555556
00:45:21.411 --> 00:45:23.726 individual asking us about aspirin?
NOTE Confidence: 0.770090885555556
00:45:23.730 --> 00:45:24.378 I think this was
NOTE Confidence: 0.865354305333333
00:45:24.390 --> 00:45:27.120 a question that was asked at the
NOTE Confidence: 0.865354305333333
00:45:27.120 --> 00:45:30.236 meeting as well and and there are none.
NOTE Confidence: 0.865354305333333
00:45:30.240 --> 00:45:32.610 I'm not sure that our, you know,
NOTE Confidence: 0.865354305333333
00:45:32.610 --> 00:45:34.085 what the European practice is,
NOTE Confidence: 0.865354305333333

00:45:34.090 --> 00:45:36.428 but I don't think that it's been,
NOTE Confidence: 0.865354305333333

00:45:36.430 --> 00:45:39.358 you know, done. It's such a.
NOTE Confidence: 0.865354305333333

00:45:39.360 --> 00:45:43.077 Such a, you know, such a nonspecific,
NOTE Confidence: 0.865354305333333

00:45:43.080 --> 00:45:44.952 you know, test among everything else
NOTE Confidence: 0.865354305333333

00:45:44.952 --> 00:45:47.038 that has been happening and being done.
NOTE Confidence: 0.865354305333333

00:45:47.040 --> 00:45:49.560 And I'm I'm not sure that
NOTE Confidence: 0.865354305333333

00:45:49.560 --> 00:45:52.030 it's being routinely done. So.
NOTE Confidence: 0.85177893

00:45:54.300 --> 00:45:56.036 The question of prophylaxis,
NOTE Confidence: 0.85177893

00:45:56.036 --> 00:45:58.206 I think that there are.
NOTE Confidence: 0.85177893

00:45:58.210 --> 00:46:01.802 There are um I, I,
NOTE Confidence: 0.85177893

00:46:01.802 --> 00:46:04.057 I it's it's hypothesis hypothesis
NOTE Confidence: 0.85177893

00:46:04.057 --> 00:46:06.402 generating and it's I wonder if
NOTE Confidence: 0.85177893

00:46:06.402 --> 00:46:08.870 it's you know if these group of
NOTE Confidence: 0.85177893

00:46:08.870 --> 00:46:10.735 patients should be separately sort
NOTE Confidence: 0.85177893

00:46:10.735 --> 00:46:12.859 of included in all the prophylaxis
NOTE Confidence: 0.85177893

00:46:12.859 --> 00:46:14.877 trials that are that are being

NOTE Confidence: 0.85177893

00:46:14.877 --> 00:46:17.886 you know undertaken and and and

NOTE Confidence: 0.85177893

00:46:17.886 --> 00:46:21.510 perhaps a more correlation you know.

NOTE Confidence: 0.85177893

00:46:21.510 --> 00:46:23.414 Those those types of studies be done

NOTE Confidence: 0.85177893

00:46:23.414 --> 00:46:24.990 including CRP and other markers.

NOTE Confidence: 0.8879602125

00:46:25.040 --> 00:46:26.480 Yeah, this is fascinating.

NOTE Confidence: 0.8879602125

00:46:26.480 --> 00:46:29.329 A lot of area for research for sure.

NOTE Confidence: 0.8879602125

00:46:29.330 --> 00:46:31.298 I'm George, I I had a

NOTE Confidence: 0.8879602125

00:46:31.298 --> 00:46:33.090 question for you as well.

NOTE Confidence: 0.8879602125

00:46:33.090 --> 00:46:36.290 In your study where or in the study

NOTE Confidence: 0.8879602125

00:46:36.290 --> 00:46:39.514 you reviewed where a splenectomy was

NOTE Confidence: 0.8879602125

00:46:39.514 --> 00:46:41.850 performed for immune cytopenias,

NOTE Confidence: 0.8879602125

00:46:41.850 --> 00:46:44.316 you noted that I think about 20% of the

NOTE Confidence: 0.8879602125

00:46:44.316 --> 00:46:46.044 patients and new diagnosis was made.

NOTE Confidence: 0.8879602125

00:46:46.050 --> 00:46:48.865 So an additional diagnosis as

NOTE Confidence: 0.8879602125

00:46:48.865 --> 00:46:50.954 presumably potentially A cause

NOTE Confidence: 0.8879602125

00:46:50.954 --> 00:46:54.002 for the immune cytopenia and I'm

NOTE Confidence: 0.8879602125

00:46:54.002 --> 00:46:56.281 wondering if the dates what the

NOTE Confidence: 0.8879602125

00:46:56.281 --> 00:46:58.540 dates of the of the study?

NOTE Confidence: 0.8879602125

00:46:58.540 --> 00:46:59.260 We're done.

NOTE Confidence: 0.8879602125

00:46:59.260 --> 00:47:01.060 And in particular I'm thinking

NOTE Confidence: 0.8879602125

00:47:01.060 --> 00:47:03.032 that with modern techniques of

NOTE Confidence: 0.8879602125

00:47:03.032 --> 00:47:04.692 flow cytometry and molecular

NOTE Confidence: 0.8879602125

00:47:04.692 --> 00:47:06.780 studies on the peripheral blood,

NOTE Confidence: 0.8879602125

00:47:06.780 --> 00:47:09.748 would we still expect to see that

NOTE Confidence: 0.8879602125

00:47:09.748 --> 00:47:12.289 high rate of an additional diagnosis

NOTE Confidence: 0.8879602125

00:47:12.289 --> 00:47:14.827 made before a splenectomy is done?

NOTE Confidence: 0.829688564

00:47:15.260 --> 00:47:16.840 It's such a good question, Bob.

NOTE Confidence: 0.829688564

00:47:16.840 --> 00:47:19.086 This abstract I think caught

NOTE Confidence: 0.829688564

00:47:19.086 --> 00:47:20.418 a lot of people off guard,

NOTE Confidence: 0.829688564

00:47:20.420 --> 00:47:21.805 especially because and of course

NOTE Confidence: 0.829688564

00:47:21.805 --> 00:47:23.190 all of these are oralists,

NOTE Confidence: 0.829688564

00:47:23.190 --> 00:47:24.550 but especially because this

NOTE Confidence: 0.829688564

00:47:24.550 --> 00:47:25.910 was a retrospective analysis.

NOTE Confidence: 0.829688564

00:47:25.910 --> 00:47:28.526 So usually don't expect such a hard hitting.

NOTE Confidence: 0.829688564

00:47:28.530 --> 00:47:30.710 Opponent because again these

NOTE Confidence: 0.829688564

00:47:30.710 --> 00:47:32.345 are consecutively treated

NOTE Confidence: 0.829688564

00:47:32.345 --> 00:47:33.980 patients with splenectomy.

NOTE Confidence: 0.829688564

00:47:33.980 --> 00:47:36.166 The years were 2002, 2020,

NOTE Confidence: 0.829688564

00:47:36.166 --> 00:47:38.480 the median follow up they did not report on,

NOTE Confidence: 0.829688564

00:47:38.480 --> 00:47:40.328 but as I was in touch with investigators

NOTE Confidence: 0.829688564

00:47:40.328 --> 00:47:41.800 they noted that they're tabulating

NOTE Confidence: 0.829688564

00:47:41.800 --> 00:47:43.405 it as they're putting together

NOTE Confidence: 0.829688564

00:47:43.405 --> 00:47:44.987 their manuscript now because I was

NOTE Confidence: 0.829688564

00:47:44.987 --> 00:47:46.319 curious you know how many years

NOTE Confidence: 0.829688564

00:47:46.320 --> 00:47:49.011 since also what was not reported

NOTE Confidence: 0.829688564

00:47:49.011 --> 00:47:51.522 and what they're looking at and the

NOTE Confidence: 0.829688564

00:47:51.522 --> 00:47:54.049 question that had asked was are these

NOTE Confidence: 0.829688564

00:47:54.049 --> 00:47:55.900 diagnostic changes and they were,

NOTE Confidence: 0.829688564

00:47:55.900 --> 00:47:57.388 I should just clarify too that

NOTE Confidence: 0.829688564

00:47:57.388 --> 00:47:58.750 investigators are calling them changes.

NOTE Confidence: 0.829688564

00:47:58.750 --> 00:48:01.738 So not only the fact was

NOTE Confidence: 0.829688564

00:48:01.738 --> 00:48:05.220 that initial indication not.

NOTE Confidence: 0.829688564

00:48:05.220 --> 00:48:06.459 They're calling the initial

NOTE Confidence: 0.829688564

00:48:06.459 --> 00:48:07.428 indication is incorrect,

NOTE Confidence: 0.829688564

00:48:07.430 --> 00:48:09.280 meaning that the entire diagnosis

NOTE Confidence: 0.829688564

00:48:09.280 --> 00:48:11.130 was switched to the postoperative

NOTE Confidence: 0.829688564

00:48:11.192 --> 00:48:13.348 diagnosis as opposed to being added on,

NOTE Confidence: 0.829688564

00:48:13.350 --> 00:48:14.454 which is interesting.

NOTE Confidence: 0.829688564

00:48:14.454 --> 00:48:16.662 And so when I asked about.

NOTE Confidence: 0.829688564

00:48:16.670 --> 00:48:18.294 Whether this was time variant or not,

NOTE Confidence: 0.829688564

00:48:18.300 --> 00:48:20.958 meaning that like let's say in the 2000s,

NOTE Confidence: 0.829688564

00:48:20.958 --> 00:48:21.534 2005 period,

NOTE Confidence: 0.829688564

00:48:21.534 --> 00:48:23.550 is that where we're catching all of

NOTE Confidence: 0.829688564

00:48:23.608 --> 00:48:25.496 those 20% or is it mostly kind of

NOTE Confidence: 0.829688564

00:48:25.496 --> 00:48:27.510 kind of the same across the board?

NOTE Confidence: 0.829688564

00:48:27.510 --> 00:48:29.328 They weren't able to answer that

NOTE Confidence: 0.829688564

00:48:29.328 --> 00:48:31.208 question only to say that it

NOTE Confidence: 0.829688564

00:48:31.208 --> 00:48:32.946 appeared that there is not like

NOTE Confidence: 0.829688564

00:48:32.946 --> 00:48:35.050 a huge spike in the early data,

NOTE Confidence: 0.829688564

00:48:35.050 --> 00:48:37.094 although it might be a little bit

NOTE Confidence: 0.829688564

00:48:37.094 --> 00:48:38.799 less moving forward it seems like,

NOTE Confidence: 0.829688564

00:48:38.800 --> 00:48:40.249 and we'll see what the manuscript shows.

NOTE Confidence: 0.829688564

00:48:40.250 --> 00:48:41.570 I won't speculate beyond that,

NOTE Confidence: 0.829688564

00:48:41.570 --> 00:48:43.682 but it seems like these misdiagnoses

NOTE Confidence: 0.829688564

00:48:43.682 --> 00:48:45.090 may still be happening.

NOTE Confidence: 0.829688564

00:48:45.090 --> 00:48:45.526 And again,

NOTE Confidence: 0.829688564

00:48:45.526 --> 00:48:46.616 I mean the Cleveland Clinic

NOTE Confidence: 0.829688564

00:48:46.616 --> 00:48:47.890 is a fantastic health system.
NOTE Confidence: 0.829688564

00:48:47.890 --> 00:48:49.668 And so if this is indeed accurate
NOTE Confidence: 0.829688564

00:48:49.668 --> 00:48:51.806 and if this is what they ultimately
NOTE Confidence: 0.829688564

00:48:51.806 --> 00:48:52.796 end up reporting,
NOTE Confidence: 0.829688564

00:48:52.800 --> 00:48:54.288 I think this is something that we all
NOTE Confidence: 0.829688564

00:48:54.288 --> 00:48:55.782 have to pay attention to because if
NOTE Confidence: 0.829688564

00:48:55.782 --> 00:48:57.609 this is happening in the Cleveland Clinic,
NOTE Confidence: 0.829688564

00:48:57.610 --> 00:48:59.522 then I don't think we're immune to that
NOTE Confidence: 0.829688564

00:48:59.522 --> 00:49:01.230 either here at Yale or anywhere else.
NOTE Confidence: 0.708265374

00:49:01.380 --> 00:49:03.080 Yeah, that's really fascinating, George.
NOTE Confidence: 0.708265374

00:49:03.080 --> 00:49:05.456 So diseases that are really truly
NOTE Confidence: 0.708265374

00:49:05.456 --> 00:49:07.576 isolated to the spleen at least
NOTE Confidence: 0.708265374

00:49:07.576 --> 00:49:08.916 by our current techniques to
NOTE Confidence: 0.708265374

00:49:08.916 --> 00:49:10.419 to discover them in the blood,
NOTE Confidence: 0.708265374

00:49:10.420 --> 00:49:13.040 yeah, that's that is fascinating.
NOTE Confidence: 0.708265374

00:49:13.040 --> 00:49:14.756 And Anish and if I may,

NOTE Confidence: 0.708265374

00:49:14.760 --> 00:49:18.110 your catheter ohso so another.

NOTE Confidence: 0.708265374

00:49:18.110 --> 00:49:19.450 So another question came in,

NOTE Confidence: 0.708265374

00:49:19.450 --> 00:49:20.650 this is for you Anish.

NOTE Confidence: 0.708265374

00:49:20.650 --> 00:49:22.948 So many factors affect the CRP

NOTE Confidence: 0.708265374

00:49:22.948 --> 00:49:26.100 level and how do you know the CRP

NOTE Confidence: 0.708265374

00:49:26.100 --> 00:49:28.398 elevation is due to the immune

NOTE Confidence: 0.708265374

00:49:28.485 --> 00:49:31.257 checkpoint inhibitor or infection?

NOTE Confidence: 0.708265374

00:49:31.260 --> 00:49:33.128 That developed afterwards perhaps.

NOTE Confidence: 0.826564288333333

00:49:33.200 --> 00:49:34.430 Yeah, it's a very good question.

NOTE Confidence: 0.826564288333333

00:49:34.430 --> 00:49:36.152 I mean it's just such a nonspecific

NOTE Confidence: 0.826564288333333

00:49:36.152 --> 00:49:37.503 marker but but there's something

NOTE Confidence: 0.826564288333333

00:49:37.503 --> 00:49:39.456 about it because you know it's a,

NOTE Confidence: 0.826564288333333

00:49:39.460 --> 00:49:41.602 it's a significant rise and it's a

NOTE Confidence: 0.826564288333333

00:49:41.602 --> 00:49:44.238 although it's a retrospectively done study,

NOTE Confidence: 0.826564288333333

00:49:44.240 --> 00:49:49.140 but it's a cohort and.

NOTE Confidence: 0.826564288333333

00:49:49.140 --> 00:49:51.812 And there there is clearly a pattern that
NOTE Confidence: 0.826564288333333

00:49:51.812 --> 00:49:54.557 has been previously recognized as well.
NOTE Confidence: 0.826564288333333

00:49:54.560 --> 00:49:56.880 So one of the citations
NOTE Confidence: 0.826564288333333

00:49:56.880 --> 00:49:59.200 that had looked into CRP,
NOTE Confidence: 0.826564288333333

00:49:59.200 --> 00:50:00.904 I don't know how you know well they
NOTE Confidence: 0.826564288333333

00:50:00.904 --> 00:50:02.538 they can adjust for other things.
NOTE Confidence: 0.826564288333333

00:50:02.540 --> 00:50:04.718 I mean these are patients with
NOTE Confidence: 0.826564288333333

00:50:04.718 --> 00:50:06.170 systemic you know metastatic
NOTE Confidence: 0.826564288333333

00:50:06.235 --> 00:50:08.669 malignancies and but they even
NOTE Confidence: 0.826564288333333

00:50:08.669 --> 00:50:11.567 previously when when they had reported.
NOTE Confidence: 0.82461002

00:50:14.930 --> 00:50:18.115 CRP Flair and and mortality or poor
NOTE Confidence: 0.82461002

00:50:18.115 --> 00:50:21.466 outcomes they they they it was a similar
NOTE Confidence: 0.82461002

00:50:21.466 --> 00:50:24.590 kind of dynamic so that it had been
NOTE Confidence: 0.82461002

00:50:24.590 --> 00:50:27.580 recognized and and so it's a good question,
NOTE Confidence: 0.82461002

00:50:27.580 --> 00:50:30.220 but it's such a such a nonspecific marker.
NOTE Confidence: 0.812899864

00:50:31.230 --> 00:50:33.670 OK, thank you. And George,

NOTE Confidence: 0.812899864

00:50:33.670 --> 00:50:34.980 if we can go back to you for a minute,

NOTE Confidence: 0.812899864

00:50:34.980 --> 00:50:41.020 the the the amide trial.

NOTE Confidence: 0.812899864

00:50:41.020 --> 00:50:41.790 Fascinating drug.

NOTE Confidence: 0.812899864

00:50:41.790 --> 00:50:44.485 And I assume that there is a

NOTE Confidence: 0.812899864

00:50:44.485 --> 00:50:46.836 potential that this could be used

NOTE Confidence: 0.812899864

00:50:46.836 --> 00:50:48.726 in any autoimmune disease where

NOTE Confidence: 0.812899864

00:50:48.803 --> 00:50:50.798 IG is felt to be the culprit.

NOTE Confidence: 0.812899864

00:50:50.800 --> 00:50:52.155 Is that how you're thinking

NOTE Confidence: 0.812899864

00:50:52.155 --> 00:50:53.239 about this as well?

NOTE Confidence: 0.752498774

00:50:53.750 --> 00:50:55.100 Well, I'll say that's how the

NOTE Confidence: 0.752498774

00:50:55.100 --> 00:50:57.880 pharmaceutical company is thinking about it.

NOTE Confidence: 0.752498774

00:50:57.880 --> 00:51:00.166 Because I've had a I've had

NOTE Confidence: 0.752498774

00:51:00.166 --> 00:51:01.690 a conversation with them.

NOTE Confidence: 0.752498774

00:51:01.690 --> 00:51:04.786 Yeah. So it was approved this,

NOTE Confidence: 0.752498774

00:51:04.790 --> 00:51:06.542 this drug was approved for my

NOTE Confidence: 0.752498774

00:51:06.542 --> 00:51:08.050 senior Gravis just last year.
NOTE Confidence: 0.752498774

00:51:08.050 --> 00:51:09.760 They're looking at it and they
NOTE Confidence: 0.752498774

00:51:09.760 --> 00:51:10.942 have obviously, as I presented,
NOTE Confidence: 0.752498774

00:51:10.942 --> 00:51:12.166 have looked at it and ITP.
NOTE Confidence: 0.752498774

00:51:12.170 --> 00:51:14.294 But I know that they're really
NOTE Confidence: 0.752498774

00:51:14.294 --> 00:51:16.965 excited about the whole host of neuro
NOTE Confidence: 0.752498774

00:51:16.965 --> 00:51:19.329 autoimmune disorders that are out there.
NOTE Confidence: 0.752498774

00:51:19.330 --> 00:51:22.426 And if it works and if it's successful,
NOTE Confidence: 0.752498774

00:51:22.430 --> 00:51:24.566 you can make an argument that
NOTE Confidence: 0.752498774

00:51:24.566 --> 00:51:26.890 this kind of mechanism could then
NOTE Confidence: 0.752498774

00:51:26.890 --> 00:51:28.945 theoretically help with any disease
NOTE Confidence: 0.752498774

00:51:28.945 --> 00:51:31.970 that has this pathologic auto antibody.
NOTE Confidence: 0.752498774

00:51:31.970 --> 00:51:34.160 Component or at least it's worth
NOTE Confidence: 0.752498774

00:51:34.160 --> 00:51:36.359 testing in any disease like that,
NOTE Confidence: 0.752498774

00:51:36.360 --> 00:51:37.848 especially if they ultimately go on
NOTE Confidence: 0.752498774

00:51:37.848 --> 00:51:39.333 to prove that the safety profile

NOTE Confidence: 0.752498774

00:51:39.333 --> 00:51:40.894 is what they claim it to be.

NOTE Confidence: 0.752498774

00:51:40.900 --> 00:51:42.895 Because as we've seen with other drugs,

NOTE Confidence: 0.752498774

00:51:42.900 --> 00:51:44.461 even phase two or phase three studies

NOTE Confidence: 0.752498774

00:51:44.461 --> 00:51:45.760 sometimes are not enough, right.

NOTE Confidence: 0.752498774

00:51:45.760 --> 00:51:47.260 When you post marketing surveillance

NOTE Confidence: 0.752498774

00:51:47.260 --> 00:51:49.070 phase four studies to really see

NOTE Confidence: 0.752498774

00:51:49.070 --> 00:51:50.455 an effect across rare diseases,

NOTE Confidence: 0.752498774

00:51:50.460 --> 00:51:51.395 presumably they're going to be

NOTE Confidence: 0.752498774

00:51:51.395 --> 00:51:52.900 looking at a lot of rare diseases,

NOTE Confidence: 0.752498774

00:51:52.900 --> 00:51:56.160 this autoimmune, neurological space.

NOTE Confidence: 0.752498774

00:51:56.160 --> 00:51:56.534 So yeah,

NOTE Confidence: 0.752498774

00:51:56.534 --> 00:51:57.656 I think there's a good amount

NOTE Confidence: 0.752498774

00:51:57.656 --> 00:51:58.359 of excitement with it.

NOTE Confidence: 0.752498774

00:51:58.360 --> 00:52:00.562 I'm curious to see what happens

NOTE Confidence: 0.752498774

00:52:00.562 --> 00:52:01.574 going forward, but.

NOTE Confidence: 0.752498774

00:52:01.574 --> 00:52:03.492 I do expect that we're going to
NOTE Confidence: 0.752498774

00:52:03.492 --> 00:52:05.710 see a dozen plus trials within next
NOTE Confidence: 0.752498774

00:52:05.710 --> 00:52:08.365 10 years in a bunch of autoimmune
NOTE Confidence: 0.752498774

00:52:08.365 --> 00:52:10.835 mediated disorders with this mechanism.
NOTE Confidence: 0.841814783571429

00:52:11.600 --> 00:52:14.000 And then presumably since B cells and plasma
NOTE Confidence: 0.841814783571429

00:52:14.000 --> 00:52:16.217 cells are not being affected directly,
NOTE Confidence: 0.841814783571429

00:52:16.220 --> 00:52:18.060 the immunosuppression will be
NOTE Confidence: 0.841814783571429

00:52:18.060 --> 00:52:20.820 less than with the drug that.
NOTE Confidence: 0.841814783571429

00:52:20.820 --> 00:52:24.236 Causes apoptosis or death of B cells present
NOTE Confidence: 0.7421815225

00:52:24.250 --> 00:52:25.612 really good. That's a really good
NOTE Confidence: 0.7421815225

00:52:25.612 --> 00:52:27.389 .1 that I hadn't actually discussed
NOTE Confidence: 0.7421815225

00:52:27.390 --> 00:52:29.020 with with the pharmaceutical company,
NOTE Confidence: 0.7421815225

00:52:29.020 --> 00:52:30.810 but one that makes a lot of sense to me.
NOTE Confidence: 0.886699574

00:52:32.790 --> 00:52:34.470 The data will tell us, I think.
NOTE Confidence: 0.886699574

00:52:34.470 --> 00:52:36.240 I think so too. Yeah,
NOTE Confidence: 0.888791608

00:52:36.280 --> 00:52:37.330 it would be nice, right?

NOTE Confidence: 0.888791608

00:52:37.330 --> 00:52:38.770 Often we're hoping that this is

NOTE Confidence: 0.888791608

00:52:38.770 --> 00:52:40.728 going to be like the next big thing.

NOTE Confidence: 0.888791608

00:52:40.730 --> 00:52:41.935 Hopefully that ends up actually

NOTE Confidence: 0.888791608

00:52:41.935 --> 00:52:43.480 being the case here. We'll see.

NOTE Confidence: 0.732658515

00:52:44.720 --> 00:52:46.305 A doctor Sharda question about

NOTE Confidence: 0.732658515

00:52:46.305 --> 00:52:48.226 the catheter study, if I may.

NOTE Confidence: 0.732658515

00:52:48.226 --> 00:52:51.000 I noted that in the catheter three study,

NOTE Confidence: 0.732658515

00:52:51.000 --> 00:52:53.610 the authors used a low molecular

NOTE Confidence: 0.732658515

00:52:53.610 --> 00:52:56.263 weight heparin for a week and

NOTE Confidence: 0.732658515

00:52:56.263 --> 00:52:58.318 then transition to a doac.

NOTE Confidence: 0.732658515

00:52:58.320 --> 00:52:59.856 Pixabay and that in in the,

NOTE Confidence: 0.732658515

00:52:59.860 --> 00:53:01.918 in the case of that study,

NOTE Confidence: 0.732658515

00:53:01.920 --> 00:53:04.770 do you think that's necessary it

NOTE Confidence: 0.732658515

00:53:04.770 --> 00:53:07.320 seems like that's excessive treatment

NOTE Confidence: 0.732658515

00:53:07.320 --> 00:53:10.155 quote excessive compared to that?

NOTE Confidence: 0.732658515

00:53:10.160 --> 00:53:10.410 I was
NOTE Confidence: 0.869618186

00:53:10.420 --> 00:53:11.390 also surprised to see that.
NOTE Confidence: 0.869618186

00:53:11.390 --> 00:53:14.084 But I think that to increase
NOTE Confidence: 0.869618186

00:53:14.084 --> 00:53:16.419 their recruitment they did that.
NOTE Confidence: 0.869618186

00:53:16.420 --> 00:53:20.472 I think most of us have a bias to I I
NOTE Confidence: 0.869618186

00:53:20.472 --> 00:53:22.680 know many people tell me like you know,
NOTE Confidence: 0.869618186

00:53:22.680 --> 00:53:24.750 you want your patient to cool off like with
NOTE Confidence: 0.869618186

00:53:24.750 --> 00:53:27.035 a heparin and then you know do something.
NOTE Confidence: 0.869618186

00:53:27.040 --> 00:53:28.330 But it, it's strange, you know,
NOTE Confidence: 0.869618186

00:53:28.330 --> 00:53:29.968 this is something that someone would do
NOTE Confidence: 0.869618186

00:53:29.968 --> 00:53:32.006 with say the bigger trend, you know,
NOTE Confidence: 0.869618186

00:53:32.006 --> 00:53:33.771 because that's what the originally
NOTE Confidence: 0.869618186

00:53:33.771 --> 00:53:35.579 studies were kind of designed.
NOTE Confidence: 0.869618186

00:53:35.580 --> 00:53:39.143 But I think this was also to
NOTE Confidence: 0.869618186

00:53:39.143 --> 00:53:40.670 increase the recruitment.
NOTE Confidence: 0.869618186

00:53:40.670 --> 00:53:43.134 And so they allowed like 7 days

NOTE Confidence: 0.869618186

00:53:43.134 --> 00:53:45.320 of of and they made a protocol,

NOTE Confidence: 0.869618186

00:53:45.320 --> 00:53:46.840 I mean everyone's treated about

NOTE Confidence: 0.869618186

00:53:46.840 --> 00:53:49.080 seven days of of of Dalteparin,

NOTE Confidence: 0.869618186

00:53:49.080 --> 00:53:50.940 Romario heparin followed by Pixar lamp,

NOTE Confidence: 0.869618186

00:53:50.940 --> 00:53:53.208 whereas it didn't do it for rivaroxaban.

NOTE Confidence: 0.842956651428571

00:53:54.190 --> 00:53:56.566 OK. And so you don't think the the

NOTE Confidence: 0.842956651428571

00:53:56.566 --> 00:53:58.805 issue was people had cancer therefore

NOTE Confidence: 0.842956651428571

00:53:58.805 --> 00:54:01.570 they might need a heparin like drug

NOTE Confidence: 0.842956651428571

00:54:01.570 --> 00:54:03.936 before they get switched to a doac?

NOTE Confidence: 0.857704832857143

00:54:04.090 --> 00:54:06.367 No, I think this is this was done rather

NOTE Confidence: 0.857704832857143

00:54:06.367 --> 00:54:08.431 quickly and this was done after you know,

NOTE Confidence: 0.857704832857143

00:54:08.431 --> 00:54:10.840 Adobe Saban and others already.

NOTE Confidence: 0.857704832857143

00:54:10.840 --> 00:54:13.620 I guess you know, you know the

NOTE Confidence: 0.857704832857143

00:54:13.620 --> 00:54:14.930 data was already out there. So

NOTE Confidence: 0.73521526

00:54:14.940 --> 00:54:17.684 OK great. I think the most most

NOTE Confidence: 0.762768184615385

00:54:17.700 --> 00:54:19.398 I think the conclude, the interesting
NOTE Confidence: 0.762768184615385

00:54:19.398 --> 00:54:21.338 thing was and this often comes up,
NOTE Confidence: 0.762768184615385

00:54:21.340 --> 00:54:25.132 which is what to do with the line I I
NOTE Confidence: 0.762768184615385

00:54:25.132 --> 00:54:28.060 liked the fact that these were real
NOTE Confidence: 0.762768184615385

00:54:28.060 --> 00:54:29.620 like symptomatic proximal events.
NOTE Confidence: 0.762768184615385

00:54:29.620 --> 00:54:32.924 I mean 3/4 of them had subclavian
NOTE Confidence: 0.762768184615385

00:54:32.924 --> 00:54:35.326 involves actually many had pulmonary
NOTE Confidence: 0.762768184615385

00:54:35.326 --> 00:54:38.902 embolisms to and they were able to save
NOTE Confidence: 0.762768184615385

00:54:38.991 --> 00:54:42.027 like like if you combine especially.
NOTE Confidence: 0.762768184615385

00:54:42.030 --> 00:54:45.327 The, the the Warfarin trial is from
NOTE Confidence: 0.762768184615385

00:54:45.330 --> 00:54:46.446 2003 four or something like that
NOTE Confidence: 0.762768184615385

00:54:46.446 --> 00:54:47.949 I think it was published in 2006.
NOTE Confidence: 0.762768184615385

00:54:47.950 --> 00:54:50.631 But at least if you combine the
NOTE Confidence: 0.762768184615385

00:54:50.631 --> 00:54:52.709 rivaroxaban and apixaban you can see
NOTE Confidence: 0.762768184615385

00:54:52.709 --> 00:54:55.062 that you know the lines can be can
NOTE Confidence: 0.762768184615385

00:54:55.062 --> 00:54:57.206 be saved without really recurrence

NOTE Confidence: 0.762768184615385
00:54:57.206 --> 00:54:59.866 or symptoms or post traumatic
NOTE Confidence: 0.762768184615385
00:54:59.866 --> 00:55:02.886 syndrome and can be used very safely.
NOTE Confidence: 0.762768184615385
00:55:02.890 --> 00:55:05.445 So that's I think is pretty good
NOTE Confidence: 0.762768184615385
00:55:05.445 --> 00:55:06.540 data to have.
NOTE Confidence: 0.827710378888889
00:55:07.190 --> 00:55:08.520 Just one follow-up question to
NOTE Confidence: 0.827710378888889
00:55:08.520 --> 00:55:10.116 you and then we'll we'll end
NOTE Confidence: 0.827710378888889
00:55:10.116 --> 00:55:11.600 and there may not be data here.
NOTE Confidence: 0.827710378888889
00:55:11.600 --> 00:55:13.464 But so if if you had a patient
NOTE Confidence: 0.827710378888889
00:55:13.464 --> 00:55:15.314 who had a symptomatic line
NOTE Confidence: 0.827710378888889
00:55:15.314 --> 00:55:17.070 associated thrombus and cancer,
NOTE Confidence: 0.827710378888889
00:55:17.070 --> 00:55:19.541 would you start at all with a
NOTE Confidence: 0.827710378888889
00:55:19.541 --> 00:55:21.029 low molecular weight heparin
NOTE Confidence: 0.827710378888889
00:55:21.029 --> 00:55:23.918 or would you just begin with a
NOTE Confidence: 0.827710378888889
00:55:23.918 --> 00:55:25.880 dull ache apixaban, let's say
NOTE Confidence: 0.779273528333333
00:55:26.250 --> 00:55:27.606 I would just begin with the,
NOTE Confidence: 0.779273528333333

00:55:27.610 --> 00:55:28.710 with the, with the doc.
NOTE Confidence: 0.7792735283333333

00:55:28.710 --> 00:55:29.695 I mean I was following the
NOTE Confidence: 0.7792735283333333

00:55:29.695 --> 00:55:31.830 River Rock Seban thing as it is
NOTE Confidence: 0.7792735283333333

00:55:31.830 --> 00:55:33.030 and now we've been using them,
NOTE Confidence: 0.7792735283333333

00:55:33.030 --> 00:55:35.730 you know, kind of interchangeably.
NOTE Confidence: 0.7792735283333333

00:55:35.730 --> 00:55:37.330 So I definitely would just,
NOTE Confidence: 0.7792735283333333

00:55:37.330 --> 00:55:38.360 you know, pick in the.
NOTE Confidence: 0.81018688

00:55:38.850 --> 00:55:41.610 Great. OK. Thank you. Well.
NOTE Confidence: 0.81018688

00:55:41.610 --> 00:55:43.080 And the hour is almost up.
NOTE Confidence: 0.81018688

00:55:43.080 --> 00:55:45.420 I'd like to thank our speakers.
NOTE Confidence: 0.81018688

00:55:45.420 --> 00:55:47.256 I these are really great abstracts
NOTE Confidence: 0.81018688

00:55:47.256 --> 00:55:49.074 you chose to present and they're
NOTE Confidence: 0.81018688

00:55:49.074 --> 00:55:51.210 some of them are clearly going to be
NOTE Confidence: 0.81018688

00:55:51.270 --> 00:55:52.908 practice changing I think for all
NOTE Confidence: 0.81018688

00:55:52.908 --> 00:55:55.149 of us and we're all excited about.
NOTE Confidence: 0.81018688

00:55:55.149 --> 00:55:57.447 Seeing these new drugs and development

NOTE Confidence: 0.81018688

00:55:57.447 --> 00:55:59.397 and new ideas brought forth.

NOTE Confidence: 0.81018688

00:55:59.400 --> 00:56:03.303 So thank you both very much and thank

NOTE Confidence: 0.81018688

00:56:03.303 --> 00:56:05.284 you to the participants who are here.

NOTE Confidence: 0.81018688

00:56:05.290 --> 00:56:07.030 We really enjoyed having you

NOTE Confidence: 0.81018688

00:56:07.030 --> 00:56:09.429 and I hope everyone has a nice

NOTE Confidence: 0.81018688

00:56:09.429 --> 00:56:11.187 rest of the day and weekend.

NOTE Confidence: 0.81018688

00:56:11.190 --> 00:56:12.999 Bye, bye now.